From owner-sci-resources@net.bio.net Mon Oct 03 23:00:00 1994 Path: biosci!biosci!not-for-mail From: BIOSCI Administrator Newsgroups: bionet.sci-resources Subject: NSF - Summary of new documents on STIS - 2 October 1994 Date: 3 Oct 1994 19:59:06 -0700 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 174 Sender: kristoff@net.bio.net Approved: biosci-moderator@net.bio.net Distribution: world Message-ID: <36qgdq$sfh@net.bio.net> NNTP-Posting-Host: net.bio.net This message contains a summary of the documents added to the NSF STIS system in the previous week. Reference material concerning STIS follows the summary. ------------------------------------------------------------------------ ** NEW DOCUMENTS ON STIS ** Document Type: News Title: TIP40923 Media Tipsheet September 23, 1994 File size (bytes): 5758 STIS Filename: tip40923 Document Type: Press Release Title: PR 94-50 THREE FEDERAL AGENCIES JOIN IN EFFORT TO INTEGRATE SCIENCE AND HUMANITIES STUDIES File size (bytes): 3609 STIS Filename: pr9450 Title: PR 94-51 RESEARCHERS SEEK BASIC KNOWLEDGE TO SUPPORT CONSERVATION AND RESTORATION File size (bytes): 12430 STIS Filename: pr9451 Title: PR 94-52 NSF ANNOUNCES AWARDS FOR DIGITAL LIBRARIES RESEARCH File size (bytes): 12541 STIS Filename: pr9452 Title: VICE PRESIDENT TO DEDICATE WORLD'S MOST POWERFUL MAGNETIC FACILITY File size (bytes): 2982 STIS Filename: pr9453 Title: PR 94-55 TECHNOLOGY TRANSFER ENCOURAGED IN NSF PROGRAM LINKING SMALL BUSINESSES TO UNIVERSITY RESEARCHERS File size (bytes): 5636 STIS Filename: pr9455 Title: READING THE "FINE PRINT" OF CLIMATE HISTORY IN GREENLAND"S ICE File size (bytes): 8482 STIS Filename: pr9456 Title: OCTOBER INAUGURATION FOR GIANT GEMINI "TWIN" TELESCOPES IN HAWAII AND CHILE File size (bytes): 3630 STIS Filename: pr9457 Document Type: Program Guideline Title: Presidential Faculty Fellows Awards File size (bytes): 25436 STIS Filename: nsf94134 Title: NSF 93-135 Faculty Early Career Development (CAREER) Program Program Characteristics FY 1995 (ALL) File size (bytes): 63653 STIS Filename: nsf94135 Title: NSF 94-144 -- Computational Approaches To Real Materials (CARM 95) File size (bytes): 11790 STIS Filename: nsf94144 Title: NSF 94-147 RESEARCH PLANNING GRANTS AND CAREER ADVANCEMENT AWARDS FOR MINORITY SCIENTISTS AND ENGINEERS File size (bytes): 43078 STIS Filename: nsf94147 Document Type: Recruit Title: Director, Division of Astronomical Sciences File size (bytes): 7991 STIS Filename: vep9414 Title: Astronomer (Program Director) File size (bytes): 4969 STIS Filename: vex9444 Title: Program Analyst File size (bytes): 5372 STIS Filename: vgs94126 Document Type: SRS Data Brief Title: DB 94-317 - 1992 R&D Spending by U.S. Firms Rises, NSF Survey Improved File size (bytes): 7878 STIS Filename: db94317 Also available: db94317.ps ------------------------------------------------------------------------ ** UPDATES TO EXISTING STIS DOCUMENTS ** Document Type: Bulletin Title: BUL 94-10 NSF October Bulletin Vol 22; No. 2 File size (bytes): 86662 STIS Filename: bul9410 Document Type: Press Release Title: PR 94-52 NSF ANNOUNCES AWARDS FOR DIGITAL LIBRARIES RESEARCH File size (bytes): 12541 STIS Filename: pr9452 Document Type: Program Guideline Title: NSF93-151--Postdoctoral Research Fellowships in Molecular Evolution File size (bytes): 33006 STIS Filename: nsf93151 Also available: nsf93151.doc Title: NSF 94-114 Postdoctoral Fellowships in Biosciences Related to the Environment File size (bytes): 27352 STIS Filename: nsf94114 Also available: nsf94114.doc Title: NSF 94-133 -- MINORITY POSTDOCTORAL RESEARCH FELLOWSHIPS AND SUPPORTING ACTIVITIES File size (bytes): 42691 STIS Filename: nsf94133 Also available: nsf94133.doc Document Type: Recruit Title: Senior Executive Service Nationwide Vacancy Listing File size (bytes): 64108 STIS Filename: sesvac ------------------------------------------------------------------------ ** FOR YOUR REFERENCE ** ------------------------------------------------------------------------ HOW TO OBTAIN DOCUMENTS The above files can be retrieved in electronic form using the STIS system. If you don't know how to use STIS, send an E-mail message to stisinfo@nsf.gov (Internet). You will receive a copy of the STIS flyer via E-mail. If you are already using STIS, you can use the information above to retrieve these files: Documents via E-mail: Send a message to stisserve@nsf.gov (Internet). Use the "STIS Filename" shown above in the "get" command. For example, to retrieve sesvac, the text of your message should be as follows: get sesvac Anonymous FTP: FTP to stis.nsf.gov. Use the "STIS Filename" shown above to retrieve a file. For example, to retrieve sesvac, you would enter: ftp> get sesvac WAIS or Gopher: Do a word search on the filename as shown in the summary. If you want a *printed* copy of a document: Send your name and postal mailing address, and the document title and number to "pubs@nsf.gov" (Internet). If you have problems with the above procedures: Send a message to "stis@nsf.gov" (Internet). From owner-sci-resources@net.bio.net Fri Oct 07 23:00:00 1994 Path: biosci!biosci!not-for-mail From: BIOSCI Administrator Newsgroups: bionet.sci-resources Subject: NIH GUIDE - RFA CA-95-002 - V23(35) 10/07/94 Date: 7 Oct 1994 18:46:18 -0700 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 512 Sender: biohelp@net.bio.net Approved: biosci-moderator@net.bio.net Distribution: world Message-ID: <374tla$itq@net.bio.net> NNTP-Posting-Host: net.bio.net $$XID RFA CA95002 CA-95-002 P1O1 *************************************** OCCUPATIONAL EXPOSURE AND CANCER PREVENTION/CONTROL RESEARCH NIH GUIDE, Volume 23, Number 35, October 7, 1994 RFA: CA-95-002 P.T. 34; K.W. 0725020, 0715035, 0745027 National Cancer Institute National Institute for Occupational Safety and Health Letter of Intent Receipt Date: January 10, 1995 Application Receipt Date: February 17, 1995 PURPOSE The Divisions of Cancer Etiology and Cancer Prevention and Control, National Cancer Institute (NCI) and the National Institute for Occupational Safety and Health (NIOSH) invite grant applications for innovative epidemiologic studies among populations occupationally exposed to potential carcinogenic substances. The purpose of this Request for Applications (RFA) is to promote cancer control research activities. Special emphasis is placed on investigating minority populations and women, who have not been studied adequately in the past, as well as small businesses, because of constraints in addressing their occupational health problems. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority areas. This RFA, Occupational Exposure and Cancer Prevention/Control Research, is related to the priority area of cancer. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017-001-00474-0) or "Healthy People 2000" (Summary Report: Stock No. 017-001-00473-1) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325 (telephone 202/783-3238). ELIGIBILITY REQUIREMENTS Applications may be submitted by domestic non-profit and for-profit institutions, public and private, such as colleges, universities, hospitals, research laboratories, units of State and local governments, and eligible agencies of the Federal government. Applications from or involving minority institutions, individuals, and women are encouraged. MECHANISM OF SUPPORT This RFA will be supported through NIH research project grants (R01). Responsibility for the planning, direction, and execution of the proposed project will be solely that of the applicant. The total project period for applications submitted in response to the present RFA may not exceed four years. This RFA is a one-time solicitation. Competing continuation applications will compete with all other unsolicited applications and be reviewed by a Division of Research Grants study section. If NCI and NIOSH determine that there is a sufficient continuing program need, the NCI and NIOSH may announce a request for new and renewal applications. NIOSH has a long-standing interest in the identification, evaluation, and control of cancers caused by occupational exposures, and NIOSH will continue to accept cancer-related grant proposals under its regular grants program announcement. FUNDS AVAILABLE The funds for this RFA come from the NCI Cancer Control budget. Approximately $2.0 million per year in total costs for four years will be committed by the NCI to specifically fund applications submitted in response to this RFA. In addition, $300,000 per year in total costs will be committed by the NIOSH to fund at least one application. This funding level is dependent on the receipt of a sufficient number of applications of high scientific merit. Because the nature and scope of the research proposed in response to this RFA may vary, it is anticipated that the size of an award will also vary. The expected number of awards is six to eight. Although this program is provided for in the financial plans of the NCI and NIOSH, the award of grants pursuant to this RFA is contingent upon the availability of funds for this purpose. RESEARCH OBJECTIVES Background The identification of occupational exposures that carry a long-term risk of disease or death is a major public health and scientific concern for the general population and especially minorities. Many well-known human carcinogens were first identified in the occupational environment on the basis of case reports by alert clinicians or pathologists. These discoveries were often serendipitous, requiring the recognition of a cluster of unusual or rare tumors in a medical practice that could be tied to an occupational exposure. Exposures and technologies in the workplace, however, are changing. Improvements in industrial hygiene and worker protection have reduced the risks of cancer in some groups. Nevertheless, exposures and risks at lower levels may remain. Many industries and occupations have reported cancer excess for which the causative agent or agents have yet to be identified. Research is needed on how occupational exposures interact with non-occupational exposures and with susceptibility factors. Occupational cancer among minority workers, inner city and rural populations is an understudied aspect of occupationally related cancer. Moreover, it has been estimated that about 5000 new chemicals are being introduced annually in the form of new commercial products, chemicals, foods, and drugs, and any potential risks are likely to be greatest and most easily detected in exposed workers. It is therefore necessary to continue evaluating the carcinogenic risks for various occupational groups. Epidemiologic studies of occupational groups are important not only to detect carcinogenic risks, but also to verify the effectiveness of reducing exposures, to define the agents responsible for the excess risk in occupations exposed to complex mixtures, and to assess how occupational agents interact with other cancer risk factors and demographic variables such as age at first exposure. It is important that information from occupational cancer studies be communicated to workers and regulatory agencies. The workers under study must be informed and educated about the potential risks associated with their employment and particular exposures. Information must also be disseminated to labor unions, industrial groups and other concerned organizations to inform workers and take necessary precautions. Improved procedures are needed to identify, trace and counsel workers who are members of specific occupational cohorts in which risks have been discovered or quantified. Modern molecular epidemiologic techniques my permit not only the direct or indirect identification of exposures to chemicals, but also the study of variations in host susceptibility that may be of genetic or environmental origin. Internal dose markers may provide an estimate of the biologically effective exposure received by an individual, or provide markers of preclinical disease response to exposure. The major goal of identifying occupational determinants of cancer is to introduce preventive measures. Occupational exposure can be controlled by the application of a number of well-known principles, including engineering techniques (substitution, isolation, and ventilation), work practices, and personal protective equipment. These principles may be applied at or near the hazard source, to the general workplace environment, or at the point of occupational exposure to individuals. Controls applied at the source of the hazard, including material substitution, process or equipment modification, isolation or automation, local ventilation, and work practices, are generally preferred and most effective in terms of both occupational and environmental concerns. Controls that may be applied to hazards that have escaped into the workplace environment include dilution ventilation, dust suppression, and housekeeping. Control measures may also be applied near individual workers, including the use of ventilated control rooms, isolation booths, supplied-air cabs, work practices, and personal protective equipment. The additional strategies for cancer control include: (l) regulation of carcinogens and appropriate substitution of agents in the work environment, (2) screening and early detection of occupationally-related cancer, (3) when appropriate, evaluation of chemopreventive agents that may inhibit the carcinogenic process, and (4) development of programs to reduce exposures (e.g., smoking) that may interact with occupational carcinogens to potentiate the risk of cancer. One area where an emphasis is needed is small businesses. The reason is that (1) the Occupational Safety and Health Administration (OSHA) is legislatively refrained from regularly inspecting businesses with 10 or fewer employees, with certain exceptions, and (2) data from NIOSH's National Occupational Exposure Survey showed that full-time health and safety services are rarely found in facilities having fewer than 50 employees. Thus, based on the OSHA constraints and NIOSH data, estimates have been made that up to 90 percent of all work sites, covering 40 percent of the total work force are not regularly inspected and do not have ready access to health and safety expertise. New research programs are needed to address the needs for health protection of workers in delivery of such materials and services in the field. Clearly a program is needed to identify potential hazards in small businesses, characterize the health and safety potential problems, develop cost-effective control recommendations and effectively transfer these recommendations to the small business sector. Research Scope and Goals The purpose of this RFA is to stimulate epidemiologic studies of cancer in the workplace and to enhance related cancer prevention and control efforts. Innovative approaches that include new diagnostic or exposure measurements are particularly encouraged. Applications that may have substantial impact on public health are encouraged. Projects should be proposed as traditional R01s. Applications that build upon ongoing research projects, utilizing already collected epidemiologic data or biospecimens, are encouraged. One important goal of this initiative is to assess the extent that occupational exposures contribute to cancer incidence and mortality among minority populations, underserved groups, and women, and to develop effective means of cancer control in these special populations. The initiative permits a wide range of epidemiologic investigations including studies directed towards modifying lifestyle behavior. Examples of areas of research that are considered to be responsive to this RFA include, but are not limited to: (1) Analytic epidemiologic studies to clarify the relation of specific occupational exposures to specific tumors, and if possible to evaluate the impact of changing exposures on time trends in cancer incidence. Once discovered, the information must be disseminated to workers in the study, and to regulatory agencies, management, unions, and other labor and industry associations. (2) Epidemiologic studies of occupational cancer that include molecular and biochemical components to more precisely identify previous exposures, intermediate outcomes or susceptibility states among particular groups of workers who are then targeted for cancer control interventions in the proposed research. Molecular epidemiologic studies could explore differences in predisposition to occupational cancer due to variations in metabolic patterns, DNA repair, formation of adducts, chromosome sensitivity to mutagens, or others, especially in minority populations and women, with appropriate cancer control interventions. The significance of biochemical or molecular analysis would be conveyed to the subjects along with suggested methods of reducing cancer risks. (3) Intervention studies with lifestyle changes, chemopreventive agents or cancer screening modalities involving population groups previously exposed to occupational carcinogens. (4) Intervention studies of engineering control, work practice modification, and use of protective equipment, with evaluation of success of interventions and assessment of applicability in other settings. (5) Cancer control intervention studies to address the impact of occupational exposures to carcinogens on the minority populations of the United States. (6) Cancer surveillance activities to utilize existing occupational data resources to identify occupational cancer risks among minority populations and women. (7) Educational interventions to inform populations-at-risk about the potential consequences of exposures to occupational carcinogens, especially as they relate to minorities and women. (8) Special research areas for small business might include the identification and characterization of potential hazards in small businesses, development of recommendations for cost effective engineering, administrative, and personal protective controls, communication of recommendations to small businesses; or education of small businesses and the public and industrial health community regarding hazards in small businesses and their control. (9) Engineering control research might include observational studies conducted in the workplace to document health hazard controls, to evaluate their performance, and to disseminate this information; investigative research to identify sources of worker exposure and subsequent development and demonstration of corrective measures. These later studies provide a much better understanding of the "etiology of occupational exposure" than previously has been possible using traditional workplace sampling. For example, it has been shown that in many cases, there are a few hazardous parts of the job that contribute most of the actual exposure. The seriousness of these exposure points was not at all apparent by observation. Intervention to control exposures at these specific hazardous points can then be much more focused, effective, supportable, and cheaper than attempts to reduce exposures without specific knowledge of the exposure profile. SPECIAL REQUIREMENTS Applicants should include, in the budget, funds for the principal investigator (and advisory board representative if a board exists) to attend an annual program meeting to be held in alternating locations of Bethesda, MD and Cincinnati, OH (or Morgantown, WV). Proposed studies must have components that provide cancer control activities, such as recommendations for substitute chemicals and for specific changes in work practices and engineering controls, informational and educational programs for workers, unions, and management, and dissemination of results to regulatory agencies, and other interested parties from labor and industry. INCLUSION OF WOMEN AND MINORITIES IN RESEARCH INVOLVING HUMAN SUBJECTS It is the policy of the NIH that women and members of minority groups and their subpopulations must be included in all NIH-sponsored biomedical and behavioral research projects involving human subjects, unless a clear and compelling rationale and justification is provided that inclusion is inappropriate with respect to the health of the subjects or the purpose of the research. This new policy results from the NIH Revitalization Act of 1993 (Section 492B of Public Law 103-43) and supersedes and strengthens the previous policies (Concerning the Inclusion of Women in Study Populations, and Concerning the Inclusion of Minorities in Study Populations) which have been in effect since 1990. The new policy contains some new provisions that are substantially different from the 1990 policies. All investigators proposing research involving human subjects should read the "NIH Guidelines on the Inclusion of Women and Minorities as Subjects in Clinical Research," which was reprinted in the Federal Register of March 28, 1994 (59 FR 14508-14513) to correct typesetting errors in the earlier publication, and reprinted in the NIH GUIDE FOR GRANTS AND CONTRACTS of March 18, 1994, Volume 23, Number 11. Investigators may obtain copies from these sources or from the program staff or contact person listed under INQUIRIES. Program staff may also provide additional relevant information concerning the policy. LETTER OF INTENT Prospective applicants are requested to submit, by January 10, 1995, a letter of intent that includes a descriptive title of the proposed research, the name, address, and telephone number of the Principal Investigator, the names of other key personnel and participating institutions, and the number and title of the RFA in response to which the application may be submitted. Although a letter of intent is not required, is not binding, and does not enter into the review of subsequent applications, the information that it contains is helpful in planning for the review of applications. It allows NCI and NIOSH staff to estimate the potential review workload and to avoid conflict of interest in the review. The letter of intent is to be sent to Dr. Richard L. Bragg at the address listed under INQUIRIES. APPLICATION PROCEDURES Applications are to be submitted on form PHS 398 (rev. 9/91) available at most institutional offices of sponsored research and from the Office of Grants Information. Division of Research Grants, National Institutes of Health, Westwood Building, Room 449, Bethesda, MD 20892, telephone 301-594-7248. The format and instructions applicable to regular research grant applications must be followed. Applicants from institutions that have a General Clinical Research Center (GCRC) funded by the NIH National Center for Research Resources may wish to identify the GCRC as a resource for conducting the proposed research. If so, a letter of agreement from either the GCRC program director or Principal Investigator could be included with the application. The RFA label available in application form PHS 398 (rev. 9/91) must be affixed to the bottom of the face page. Failure to use this label could result in delayed processing of the application such that it may not reach the review committee in time for review. In addition, the number and title of the RFA must be typed on line 2a of the face page of the application and YES must be checked. Submit a signed, typewritten original of the application, including the Checklist, and three signed, exact, clear and single-sided photocopies, in one package to: Division of Research Grants National Institutes of Health Westwood Building, Room 240 Bethesda, MD 20892** At the time of submission, applicants must send two additional copies of the application to: Ms. Toby Friedberg Division of Extramural Activities National Cancer Institute 6130 Executive Boulevard MSC 7405 Executive Plaza North, Room 636 Bethesda, MD 20892-7405 Failure to submit these copies may delay the review and subsequent possible consideration of an application for award in FY 1995. Applications must be received by February 17, 1995. If an application is received after that date, it will be returned without review. If the application submitted in response to this RFA is substantially similar to a research grant application already submitted to the NIH for review, but has not yet been reviewed, the applicant will be asked to withdraw either the pending application or the new one. Simultaneous submission of identical applications will not be allowed, nor will essentially identical applications be reviewed by different review committees. Therefore, an application cannot be submitted in response to this RFA that is essentially identical to one that has already been reviewed. This does not preclude the submission of substantial revisions of applications already reviewed, but such applications must include an introduction addressing the previous critique. REVIEW CONSIDERATIONS Upon receipt, applications will be reviewed for completeness by DRG and responsiveness by the NCI and NIOSH. Incomplete applications will be returned to the applicant without further consideration. If NCI and NIOSH staff find that the application is not responsive to the RFA, it will be returned without further consideration. Applications that are complete and responsive to the RFA will be evaluated for scientific and technical merit by an appropriate peer review group convened by the NCI in accordance with the review criteria stated below. As part of the initial merit review, a process (triage) may be used by the initial review group in which applications will be determined to be competitive or non-competitive based on their scientific merit relative to other applications received in response to the RFA. Applications judged to be competitive will be discussed and be assigned a priority score. Applications determined to be non-competitive will be withdrawn from further consideration and the principal investigator/program director and the official signing for the applicant organization will be promptly notified. The second level of review by the National Cancer Advisory Board considers the special needs of the NCI and the priorities of the National Cancer Program. The second level of review by NIOSH will consider the number of workers affected by the hazard under study and the potential contribution to applied technical knowledge in the prevention of occupational cancers. Review criteria for RFAs are the same as those for unsolicited research grant applications: o scientific, technical, or medical significance and originality of proposed research; o appropriateness and adequacy of the experimental approach and methodology proposed to carry out the research; o qualifications and research experience of the Principal Investigator and staff, particularly but exclusively in the area of the proposed research; o availability of resources necessary to perform the research. o Adequacy of plans to include both genders and minorities and thier subgroups as appropriate for the scientific goals of the research. Plans for the recruitment and retention of subjects will also be evaluated. The review group will critically examine the submitted budget and will recommend an appropriate budget and period of support for each scored application. AWARD CRITERIA The earliest anticipated date of award is September 29, 1995. Applications will compete for available funds with all other approved applications. The following will be considered in making funding decisions: o quality of the proposed project as determined by peer review; o reasonableness of the budget in comparison with other applications; o program balance among research areas. INQUIRIES Inquiries concerning this RFA are encouraged. The opportunity to clarify any issues or questions from potential applicants is welcome. Richard L. Bragg, Ph.D. Division of Cancer Prevention and Control National Cancer Institute 6130 Executive Boulevard MSC 7395 Executive Plaza North, Suite 240 Bethesda, MD 20892-7395 Telephone: (301) 496-8589 FAX: (301) 496-8675 A.R. Patel, Ph.D. Divisionof Cancer Etiology National Cancer Institute 6130 Executive Boulevard MSC 7395 Executive Plaza NOrth, Suite 535 Bethesda, MD 20892-7395 Telephone: (301) 496-9600 FAX: (301) 402-4279 Roy M. Fleming, Sc.D. National Institute of Occupational Safety and Health 1600 Clinton Road, NE Building l, Room 3053, Mail Stop D-30 Atlanta, GA 30333 Telephone: (404) 639-3343 FAX: (404) 639-2196 Email: rmf2@niood1.em.cdc.gov Direct inquiries regarding fiscal matters to: Ms. Cynthia Mead Grants Research Branch National Cancer Institute 6120 Executive Boulevard MSC 7395 Executive Plaza South, Suite 243 Bethesda, MD 20892-7395 Telephone: (301) 496-7800, Ext. 254 AUTHORITY AND REGULATIONS This program is described in the Catalog of Federal Domestic Assistance Nos. 93.393 and 93.894. Awards are made under authorization of the Public Health Service Act, Title IV, Part A (Public Law 78-140, as amended by Public Law 99.158, 42 USC 241 and 285) and administered under HHS policies and grant regulations. This program is not subject to the intergovernment review requirements of Executive Order 12372 or Health System Agency review. The Public Health Service strongly encourages all grant recipients to provide a smoke-free workplace and promote the non-use of all tobacco products. This is consistent with the PHS mission to protect and advance the physical and mental health of the American people. From owner-sci-resources@net.bio.net Fri Oct 07 23:00:00 1994 Path: biosci!biosci!not-for-mail From: BIOSCI Administrator Newsgroups: bionet.sci-resources Subject: NIH GUIDE - RFA DK-95-001 - V23(35) 10/07/94 Date: 7 Oct 1994 18:46:28 -0700 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 457 Sender: biohelp@net.bio.net Approved: biosci-moderator@net.bio.net Distribution: world Message-ID: <374tlk$iuu@net.bio.net> NNTP-Posting-Host: net.bio.net $$XID RFA DK95001 DK-95-001 P1O1 *************************************** DIABETES RESEARCH AND TRAINING CENTER NIH GUIDE, Volume 23, Number 35, October 7, 1994 RFA: DK-95-001 P.T. 04; K.W. 0715075, 0720005, 0710030 National Institute of Diabetes and Digestive and Kidney Diseases Letter of Intent Receipt Date: February 16, 1995 Application Receipt Date: March 16, 1995 PURPOSE The National Institute of Diabetes, Digestive and Kidney Diseases (NIDDK) supports six Diabetes Research and Training Centers (DRTCs). These Centers are part of an integrated program of diabetes-related research support within the NIDDK. Centers have provided a focus for increasing the efficiency and collaborative effort among groups of successful investigators at institutions with established comprehensive diabetes research bases. The NIDDK invites applications for funding of one DRTC grant to be competitively awarded in Fiscal Year 1996. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority areas. This Request for Applications, (RFA), Diabetes Research and Training Centers, is related to the priority area of diabetes mellitus. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017-001-00474-0) or "Healthy People 2000" (Summary Report: Stock No. 017-001-00473-1) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325 (telephone (202) 783-3238). ELIGIBILITY REQUIREMENTS Applications may be submitted by domestic for-profit and non-profit organizations, public and private, such as universities, colleges, hospitals, laboratories, units of State and local governments, and eligible agencies of the Federal government. Minority individuals and women are encouraged to submit as Principal Investigators. Any institution with an outstanding, existing program of biomedical research in the area of diabetes may apply for a DRTC. In addition, existing Diabetes Endocrinology Research Centers (DERCs) may submit competing applications for conversion to DRTCs. Foreign institutions are not eligible to apply. MECHANISM OF SUPPORT This RFA is a one time solicitation. Support of this program will be through the National Institutes of Health (NIH) comprehensive center (P60) award. Responsibility for the planning, direction, and execution of the proposed project will be solely that of the applicant. In addition to the requirements stated in this RFA, awards will be administered under PHS grants policy as stated in the PHS Grants Policy Statement. FUNDS AVAILABLE The NIDDK anticipates awarding one DRTC Grant in Fiscal Year 1996 on a competitive basis. The receipt of one competing continuation application is anticipated, which will be in competition together with the other applications received in response to this RFA. The anticipated award will be contingent upon the availability of appropriated funds. Requests for support must be limited to no more than $1,250,000 in direct costs per year. Requests for support for Demonstration and Education (D&E) supplements to convert an existing DERC to a DRTC must be limited to $300,000 in direct costs. If awarded, the D&E supplement funding would be added to the level of the existing DERC budget. The $1,250,000 direct cost application limit would then apply to future DRTC competing renewals. The NIDDK has allocated $1,657,000 in total costs to support this RFA. Any application exceeding the direct cost amounts indicated will be returned to the applicant without review. RESEARCH OBJECTIVES The NIDDK-supported Diabetes Centers program is comprised of DERCs and DRTCs. The objective of the Diabetes Research Center is to bring together investigators from relevant disciplines in a manner which will enhance and extend the effectiveness of research and training being conducted in the field of diabetes and its complications. These Centers have provided a focus for increasing collaboration and cost effectiveness among groups of successful investigators at institutions with established comprehensive diabetes research bases. Both types of centers are based on the core concept. Cores are defined as shared resources that enhance productivity or in other ways benefit a group of investigators working in diabetes or diabetes-related areas to accomplish the stated goals of the Center. These centers also support a pilot and feasibility program and an enrichment program. The pilot and feasibility program provides modest support for new initiatives or feasibility research studies for new investigators or for established investigators in other research disciplines when their expertise may be applied to diabetes research. These include biomedical, epidemiologic, behavioral, and health care research as it pertains to the Center's mandate for the training of primarily health care professionals. The Center grant may also include limited funds for program enrichment such as seminars, visiting scientists, consultants, workshops, etc. While the above components are common to DERCs and DRTCs, DRTCs also include a substantial additional component, the Demonstration and Education (D&E) Division. The D&E Division: (1) carries out training programs for health care professionals, (2) is engaged in research in the translation of the outcomes of biomedical and behavioral science research into clinical care, and (3) develops, tests, and evaluates innovative methods and programs for translation activities. These features are described briefly in this RFA and in detail in the DRTC Guidelines. Each project or core within the D&E Division may not exceed 25 pages. A DERC is eligible to apply for conversion to the DRTC program. An existing DERC that elects to apply for such conversion in response to this RFA must follow the following procedures: (1) if the DERC will have at least one year of support remaining as of December 1, 1995 (the earliest funding date for applications submitted in response to this RFA), a competing supplement to the existing DERC may be submitted which includes only the components of a Demonstration and Education Division. In addition, information (limited to five pages) should be included describing how this D&E addition will interact with the existing DERC elements and enhance the comprehensive nature of the Center. A successful competition would result in the DERC being converted to a DRTC for the duration of that Center's current award. It would then be eligible to submit a DRTC proposal for its competing renewal. (2) If the DERC will have less than one year of support remaining after December 1, 1995, it must submit a full DRTC application. If funded the DRTC would have a five year award period. A DRTC must be an identifiable unit within a single university, medical center or a consortium of cooperating institutions, including an affiliated university. The overall goal of the DRTC is to bring together on a cooperative basis, clinical and basic science investigators and those involved in diabetes education and translation. As indicated above, the DRTCs are expected to encompass the following: (1) facilitate and strengthen basic and clinical research related to diabetes and its complications; (2) train health professionals about diabetes and its management. In addition, within the D&E Division of the DRTC: (3) develop a model demonstration facility to contribute to the above endeavors; and, (4) translate advances in the field of diabetes into improved care, especially, the translation of the intensive management shown to be effective by the Diabetes Control and Complications Trial (DCCT). The latter should focus on research to identify and overcome barriers to intensive diabetes management and treatment. All of these areas need not be developed to the same degree. A strong base of biomedical research is an essential prerequisite of a Center. Accordingly, a program of excellence in biomedical research in the area of diabetes and related metabolic and endocrine disorders in the form of NIH-funded research projects, program projects, or other peer-reviewed research must be in existence at the time of submission of a Center application. Close cooperation, communication, and collaboration among all involved personnel of all professional disciplines to enhance research progress are ultimate objectives. Applicants should request a copy of the DRTC guidelines and consult with NIDDK staff concerning plans for the development of the Center. Applicants from institutions that have a General Clinical Research Center (GCRC) funded by the NIH National Center for Research Resources may wish to identify the GCRC as a resource for conducting the proposed research. If so, a letter of agreement from either the GCRC program director or Principal Investigator should be included with the application. INCLUSION OF WOMEN AND MINORITIES IN RESEARCH INVOLVING HUMAN SUBJECTS It is the policy of the NIH that women and members of minority groups and their subpopulations must be included in all NIH supported biomedical and behavioral research projects involving human subjects, unless a clear and compelling rationale and justification is provided that inclusion is inappropriate with respect to the health of the subjects or the purpose of the research. This new policy results from the NIH Revitalization Act of 1993 (Section 492B of Public Law 103-43) ad supersedes and strengthens the previous policies (Concerning the Inclusion of Women in Study Populations, and Concerning the Inclusion of Minority in Study Populations) which have been in effect since 1990. The new policy contains some new provisions that are substantially different from the 1990 policies. All investigators proposing research involving human subjects should read the "NIH Guidelines For Inclusion of Women and Minorities as Subjects in Clinical Research," which have been published in the Federal Register of March 28, 1994 (FR 59 14508-14513), and in the NIH Guide for Grants and Contracts, Volume 23, Number 11, March 18, 1994. Investigators also may obtain copies of the policy from program staff listed under INQUIIRIES. Program staff may also provide additional relevant information concerning the policy. LETTER OF INTENT Prospective applicants are asked to submit, by February 16, 1995, a letter of intent that includes a descriptive title of the proposed research, the name, address, and telephone number of the Principal Investigator, the identities of other key personnel and participating institutions, and the number and title of the RFA in response to which the application may be submitted. Although a letter of intent is not required, is not binding, and does not enter into the review of subsequent applications, the information that it contains is helpful in planning for the review of applications. It allows NIDDK staff to estimate the potential review workload and to avoid possible conflict of interests in the review. Prospective applicants may submit letters of intent to: Chief, Review Branch Division of Extramural Activities National Institute of Diabetes and Digestive and Kidney Diseases 45 Center Drive MSC 6600 Bethesda, MD 20892-6600 APPLICATION PROCEDURES Applicants are strongly encouraged to request a copy of "Guidelines for Diabetes Research and Training Centers." These guidelines contain important suggestions and information on the format, content, and review of applications and review criteria. Prospective applicants may obtain guidelines from the program official listed under INQUIRIES. Applications are to be submitted on the form PHS 398 (rev. 9/91) available at most institutional offices of sponsored research and from the Office of Grants Information, Division of Research Grants, National Institutes of Health, 5333 Westbard Avenue, Room 449, Bethesda, MD 20892, telephone (301) 594-7248. The RFA label available in the PHS 398 (rev. 9/91) application form must be affixed to the bottom of the face page of the application. Failure to use this label could result in delayed processing of the application such that it may not reach the review committee in time for review. In addition, the RFA title and number must be typed on line 2a of the face page of the application form and the YES box must be marked. Submit a signed, typewritten original of the application, including the Checklist, plus three signed, exact photocopies, in one package to: Division of Research Grants National Institutes of Health Westwood Building, Room 240 Bethesda, MD 20892** At time of submission, two additional copies of the application must also be sent under separate cover to: Chief, Review Branch Division of Extramural Activities National Institute of Diabetes and Disgestive and Kidney Diseases 45 Center Drive MSC 6600 Bethesda, MD 20892-6600 Applications must be received by March 16, 1995. If an application is received after that date, it will be returned to the applicant. The DRG will not accept any application that is essentially the same as one already reviewed. This does not preclude the submission of substantial revisions of applications previously reviewed. Such applications must not only include an introduction addressing the previous critique but also be responsive to this RFA. REVIEW CONSIDERATIONS Applications that are complete and responsive to the RFA will be evaluated for scientific and technical merit by an appropriate peer review group convened by the NIDDK in accordance with the review criteria stated below. As part of the initial merit review, a process (triage) may be used by the initial review group in which applications will be determined to be competitive or non-competitive based on the scientific merit relative to other applications received in response to the RFA. Applications judged to be competitive will be discussed and be assigned a priority score. Applications determined to be non-competitive will be withdrawn from further consideration and the principal investigator/program director and the official signing for the applicant organization will be promptly notified. It is essential that the written application be in a form to be reviewed on its own merit, since no site-visit is anticipated. Following this review, the applications will be given a second level review by the National Diabetes and Digestive and Kidney Diseases Advisory Council. The initial review group will review each application using the criteria stated below and detailed in the DRTC Guidelines: New and Competing DRTC Applications: 1. Biomedical Research o Scientific excellence of the Center's research base that must have a broad and central focus in diabetes and may extend to related research in metabolism and endocrinology. The relevance of the separately funded research to the DRTC objectives (see above) and the likelihood for meaningful collaboration among Center investigators must be demonstrated. o Potential of the cores for contribution to ongoing research, their appropriateness and relevance, their modes of operation and, suitability of facilities. Renewal applications must include the use, utility, quality control, cost effectiveness, and demonstrated progress of any developmental research in the shared resources. o For new applications, the pilot and feasibility program is judged on the basis of: (1) scientific merit of the studies as submitted and (2) the merit of the administrative process for selecting subsequent studies. In competitive renewal applications, emphasis is placed on the program as a whole, including past track record and management of the program. o Adequacy of plans to include both genders and minorities and their subgroups as apropriate for the scientific goals of the research. Plans for the recruitment and retention of subjects will also be evalusted. 2. Research Training o Although the Center does not specifically support research training, demonstration of accomplishments and future plans related to the training of investigators necessary to conduct research in diabetes and related metabolic and endocrine disorders will be considered in assessing the potential to meet Center objectives. The integration of these efforts into the overall Center, including core facilities is of particular importance. 3. Demonstration and Education o The applicant's existing or planned activities to overcome barriers to translating research knowledge into improved diabetes health care will be evaluated on the basis of: (a) The novelty, feasibility, and quality of programs, materials, and publications that address overcoming barriers to translation of scientific advances into clinical practice. This should include program and/or curriculum development in the education of health care professionals (including students) both within and outside the DRTC. Completed programs and materials should be translatable to other settings and should have undergone some form of evaluation. (b) Organization and use of the Model Demonstration Unit which is a required component of the DRTC. The MDU should include as a central mission the development, testing, and demonstration of model diabetes care. Ideally it should span all the Center activities, including basic and clinical research, research training and training of health professionals. (c) For existing Centers, future plans for continuing ongoing activities and initiating new activities and their evaluation. (d) The approach, results, and general utility of any outreach projects, including: transferability to other settings, demonstrated effectiveness, and plans for take over by local groups and/or funding from other sources. (e) Overall coordination and cooperation within the D&E component among the cores of the DRTC and with other groups (voluntary health organizations, Federal agencies, and other diabetes-related efforts, etc.). (f) Consideration of the potential impact of the activity on the national diabetes effort. 4. Supplemental Demonstration and Education Unit Applications: o The supplement will be evaluated on the basis of the D&E criteria presented above. o The D&E supplement should carefully present the rationale for extending the currently funded DERC to include this new element. o The interfacing of the additional D&E element to the existing DERC. How does this extension impact on the overall activities of the Center? o The overall rating of the DERC plus D&E supplement for conversion to a DRTC will be based on the above stated D&E criteria in addition to the existing DERC framework. The latter will take into consideration the previous DERC Summary Statement. The DERC elements will not be re-reviewed. 5. Administration o The scientific and administrative leadership abilities of the DRTC Director and Associate Director and their commitment and ability to devote adequate time to the effective management of the DRTC program. o The appropriateness of the DERC budgets for the proposed and approved work to be done in core facilities, for pilot and feasibility studies, and for enrichment in relation to the total Center program. o Efficiency and effectiveness of use and/or planned use of enrichment funds. o Institutional commitment to the program, including lines of accountability regarding management of the DERC grant and a commitment to establish new positions as necessary. AWARD CRITERIA The anticipated date of the award is December 1, 1995. Applications will compete for available funds with all other applications submitted in response to this RFA and recommended by peer review. The following will be considered in making funding decisions: o Quality of the proposed Center as determined by peer review o Availability of funds INQUIRIES Inquiries concerning this RFA are encouraged. The opportunity to clarify any issues or questions from potential applicants is welcome. Dr. Sanford A. Garfield Division of Diabetes, Endocrinology, and Metabolic Diseases National Institute of Diabetes and Digestive and Kidney Diseases Westwood Building, Room 626 45 Center Drive MSC 6600 Bethesda, MD 20892-6600 Telephone: (301) 594-7535 FAX: (301) 594-9011 Email: sandyg@dvsgate.niddk.nih.gov Direct inquiries regarding fiscal matters to: Ms. Linda Stecklein Division of Extramural Activities National Institute of Diabetes and Digestive and Kidney Diseases Westwood Building, Room 653 45 Center Drive MSC 6600 Bethesda, MD 20892-6600 Telephone: (301) 594-7543 Schedule Letter of Intent Receipt Date: February 16, 1995 Application Receipt Date: March 16, 1995 Initial Review Dates: June-July 1995 Second Level Review Dates: Sep-Oct 1995 Anticipated Award Date: December 1, 1995 AUTHORITY AND REGULATIONS This program is described in the Catalog of Federal Domestic Assistance No. 93.847. Awards are made under authorization of the Public Health Service Act, Title IV, Part A (Public Law 78-410, as amended by Public Law 99-158, 42 USC 241 and 285) and administered under PHS grants policies and Federal Regulations 42 CFR 52 and 45 CFR Part 74. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review. The Public Health Service strongly encourages all grant recipients to provide a smoke-free workplace and promote the non-use of all tobacco products. This is consistent with the PHS mission to protect and advance the physical and mental health of the American people. From owner-sci-resources@net.bio.net Fri Oct 07 23:00:00 1994 Path: biosci!biosci!not-for-mail From: BIOSCI Administrator Newsgroups: bionet.sci-resources Subject: NIH GUIDE - PA-95-001 - V23(35) 10/07/94 Date: 7 Oct 1994 18:46:01 -0700 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 243 Sender: biohelp@net.bio.net Approved: biosci-moderator@net.bio.net Distribution: world Message-ID: <374tkp$ir6@net.bio.net> NNTP-Posting-Host: net.bio.net $$XID RFA PA95001 PA-95-001 P1O1 *************************************** FACTORS THAT DETERMINE THERAPEUTIC DRUG BIOAVAILABILITY NIH GUIDE, Volume 23, Number 35, September 30, 1994 PA NUMBER: PA-95-001 P.T. 34; K.W. 0740020, 0755025 National Institute of General Medical Sciences PURPOSE The purpose of this program announcement (PA) is to encourage basic research in the areas that are fundamental to understanding the factors that determine therapeutic drug bioavailability, with emphasis on the oral route of delivery. ELIGIBILITY REQUIREMENTS Applications may be submitted by domestic and foreign, for-profit and not-for-profit organizations, public and private, such as universities, colleges, hospitals, laboratories, units of State and local governments, eligible agencies of the Federal government, and small businesses. Applications from minority individuals and women are particularly encouraged. Foreign institutions are not eligible to receive First Independent Research Support and Transition (FIRST) awards (R29) or program project grants (P01). For-profit applicants for the Small Business Innovation Research (SBIR) program (R43, R44) and the Small Business Technology Transfer Research (STTR) program (R41, R42) must qualify as a small business concern in accordance with the definition given in the latest edition of the Omnibus Solicitation of the Public Health Service for Small Business Innovation (SBIR) Grant and Cooperative Agreement Applications, and the Omnibus Solicitation of the National Institutes of Health for Small Business Technology Transfer Research (STTR) Applications. Additional eligibility requirements for SBIR and STTR applicants, including organizational, principal investigator, and performance site criteria are described in these Omnibus Solicitations. MECHANISMS OF SUPPORT Support of this program announcement will be through individual research project grants (R01), FIRST awards (R29), program project (P01) grants, and awards to small businesses under the Small Business Innovation Research (SBIR) program (R43, R44) and the Small Business Technology Transfer Research (STTR) program (R41, R42). Investigators with ongoing R01, R37 (Method to Extend Research in Time (MERIT)) and P01 awards who are expanding the scope of their work and would have at least one year of support remaining from the anticipated date of award may apply for competing supplement awards. RESEARCH OBJECTIVES Bioavailability represents an area of basic research that has received little emphasis to date. The economic consequences of problems with drug bioavailability are enormous. Many potential drug candidates have failed as a result of difficulties in penetrating barriers or not arriving or remaining in active form at the site of action. Drug candidates can be tested for their desired therapeutic activity, but it is not yet possible to predict whether or not a compound will have sufficient bioavailability to be useful and practical. The National Institute of General Medical Sciences (NIGMS) wants to encourage research in several different fundamental areas in order to optimize the bioavailability of newly designed therapeutic entities, and to develop strategies to predict how a drug candidate will perform based on its chemical structure. Because comprehensive understanding of the basic biology of how a drug gets to the site of action and overcomes the obstacles it encounters is currently quite limited, mechanistic research is encouraged in the areas that determine the physiological, pharmacological, biological, and chemical processes that contribute to drug absorption, metabolism, transport, or clearance. Overall, these studies may include, but are not limited to studies on: o integrating information useful for maximizing drug bioavailability at the drug design stage o generating strategies to predict the bioavailability of drug candidates intended for use in humans Basic research is encouraged in the areas of mechanisms determination, models validation, structure-activity relationships, formulations, methods development, and determining intra-/interindividual differences. Emphasis will be placed on, but not limited to, the oral route of drug delivery. Investigations that involve the interactions of physical and biological scientists (e.g., chemists, biologists, clinicians) are particularly encouraged. Liaisons between academic, industrial, and eligible government laboratories are also encouraged. Possible example research areas include: o investigation of the molecular mechanisms of active and passive transport processes of the gastrointestinal tract, liver, kidney, and lung, that determine drug absorption, metabolism, transport, or clearance o characterization of human metabolic enzymes, their isoforms and their heterogeneous distribution, that determine drug absorption, metabolism, transport, or clearance o identification of regional differences or site-specific processes within an organ system, that contribute to drug absorption, metabolism, transport, or clearance o investigation of interactions between the organ systems in humans, that contribute to drug absorption, metabolism, transport, or clearance o design and validation of predictive in vitro tests, based upon human information and comparison to existing established models o integrated modelling of all processes that in concert determine drug absorption, metabolism, transport, or clearance in humans o establishment of compound libraries to examine drug absorption, metabolism, transport, or clearance, that can be used to provide drug structural/functional predictive information o identification of pro-drug strategies that harness or circumvent carriers or enzymes of drug absorption, metabolism, transport, or clearance o identification of formulation approaches that take advantage of known routes for drug absorption, metabolism, transport, or clearance or devise new methods for delivery o development of analytical techniques with increased sensitivity, accuracy, speed, and simplicity for measuring drug absorption, metabolism, transport, or clearance o influence of age-based, sex-based, racially-based, disease-based, or other interindividual differences in drug absorption, metabolism, transport, or clearance o influence of polytherapy, food intake, nutritional status, or other intraindividual differences in drug absorption, metabolism, transport, or clearance APPLICATION PROCEDURES Applicants for research project grants (R01, R29), program project grants (P01), and supplemental awards are to use the regular grant application form PHS 398 (rev. 9/91). Application receipt dates are listed in the PHS 398. Application kits are available at most institutional offices of sponsored research and may be obtained from the Office of Grants Information, Division of Research Grants, National Institutes of Health, Westwood Building, Room 449, Bethesda, MD 20892, telephone (301) 594-7248. Applications for the SBIR program will be accepted for the usual receipt dates: April 15, August 15, and December 15. Applications for the STTR program, phase I (R41) will be accepted for December 1, 1994. Applicants should consult future publications of the Omnibus Solicitation of the NIH for STTR Applications for additional receipt dates. Application kits are available from MTL, Inc., 13687 Baltimore Avenue, Laurel, MD 20707-5096, telephone (301) 206-9385; FAX (301) 206-9722; Internet a2y@cu.nih.gov. All individuals applying under this announcement must cite this program announcement by title and number. The application should clearly state how the scientific objectives of the proposed research will enhance the basic understanding of the factors that determine drug bioavailability in humans. On the face page of the application form PHS 398, item 2a, the word "YES" must be checked, and the title and number of this program announcement must be inserted in the space provided. FIRST applications must include the three sealed letters of reference attached to the face page of the original application, or the applications will be considered incomplete and will be returned to the applicant. The completed original application and five copies must be sent or delivered to: Division of Research Grants National Institutes of Health Westwood Building, Room 240 Bethesda, MD 20892** REVIEW CONSIDERATIONS Applications will be assigned to an initial review group (IRG) and to a funding component (institute) based upon established Public Health Service referral guidelines. IRGs will review the applications for scientific and technical merit in accordance with the usual NIH peer review procedures. Following the IRG reviews, applications will receive a second level of review by the appropriate National Advisory Council. AWARD CRITERIA Applications will compete for funds with other approved applications. The following criteria will be considered when making funding decisions: o Quality of the proposed project as determined by peer review o Availability of funds o Significance of the proposed research to the aims of this program announcement o Program diversity and balance INQUIRIES Inquiries are encouraged. The opportunity to clarify any issues or questions from potential applicants is welcome. Direct inquiries regarding programmatic issues to: Rochelle M. Long, Ph.D. Pharmacology and Biorelated Chemistry Program National Institute of General Medical Sciences 45 Center Drive, Box 6200 Bethesda, MD 20892 Telephone: (301) 594-7808 FAX: (301) 594-7728 Email: LONG@GM1.NIGMS.NIH.GOV Direct inquiries regarding financial matters to: Ms. Toni Holland National Institute of General Medical Sciences 45 Center Drive, Box 6200 Bethesda, MD 20892 Telephone: (301) 594-7819 FAX: (301) 594-8891 Email: HOLLANDA@GM1.NIGMS.NIH.GOV AUTHORITY AND REGULATIONS This program is described in the Catalog of Federal Domestic Assistance number 93.859 (Pharmacology and Biorelated Chemistry). Awards will be made under the Public Health Service Act, Titles III and IV (Public Law 78-410, as amended by Public Law 99-158, 42 USC 241 and 287) and administered under PHS grants policies and Federal Regulations 42 CFR part 52 and 45 CFR Part 92. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review. The Public Health Service (PHS) strongly encourages all grant recipients to provide a smoke-free workplace and promote the non-use of all tobacco products. This is consistent with the PHS mission to protect and advance the physical and mental health of the American people. From owner-sci-resources@net.bio.net Fri Oct 07 23:00:00 1994 Path: biosci!biosci!not-for-mail From: peapud@rpi.edu (Diane Hope Peapus) Newsgroups: bionet.general,bionet.announce,comp.research.japan,bionet.sci-resources Subject: NSF Summer in Japan for grad students Date: 7 Oct 1994 18:40:16 -0700 Organization: Rensselaer Polytechnic Institute, Troy NY Lines: 115 Sender: biohelp@net.bio.net Approved: bionews-moderator@net.bio.net Distribution: usa Message-ID: <373par$ppf@usenet.rpi.edu> NNTP-Posting-Host: net.bio.net Xref: biosci bionet.general:11456 bionet.announce:1470 comp.research.japan:826 bionet.sci-resources:1122 Greetings: This as an announcement about a really good opportunity for anyone who is a grad student, or will be a grad student, and is interested in spending a summer doing research in Japan. The program allows you to find a Japanese "host", whose research is somewhat compatable to your own, or attempts to match you to a Japanese host in your general area, if you have no host of your own in mind. I went last year and collected data that will be used in my postdoc work, as well as collecting data for other people in my lab. Please feel free to distribute the announcement to anyone that you think will be interested. Anyone wanting additional info about what it was really like, is free to contact me at... diane@cwxtl.bioc.cwru.edu diane h peapus 216-368-8682 ______________________________________________________________ From: jcassidy@nsf.gov To: si90@nsf.gov, si91@nsf.gov, si92@nsf.gov, si93@nsf.gov, si94@nsf.gov Subject: Summer Institute 1995 Date: 6 Oct 94 10:47 EST Dear Alumni: The NSF Japan Program would appreciate it if you would please distribute the following email advertisement to any and all appropriate people, places, etc. Please encourage your colleagues, friends, and students to apply! We are still receiving about 120-130 applications a year and are selecting 60 people. The odds are good! Thanks, Janice Cassidy Japan Program/NSF --------------------------- TO: Interested applicants FROM: NSF Japan Program SUBJECT: 1995 Summer Institute in Japan -------------------------------------------- NSF and NIH announce an opportunity for graduate students.... ** the 1995 SUMMER INSTITUTE IN JAPAN *** for U.S. Graduate Students in Science and Engineering, Including Biomedical Science and Engineering. APPLICATION DEADLINE: December 1, 1994 Program's Goal: to provide U.S. graduate students first- hand experience in a Japanese research laboratory. Program Elements: ** Internship at a Japanese government, corporate or university laboratory in Tokyo or Tsukuba; ** Intensive Japanese language training; ** Lectures on Japanese science, history, culture, etc. Program Duration and Dates: 8 weeks; June 23 to August 19, 1995. Eligibility requirements: 1. U.S. citizens or permanent residents 2. Enrolled at a U.S. institution in a science or engineering Ph.D. program, Enrolled in an M.D. program and have an interest in biomedical research, or Enrolled in an engineering M.S. program of which one year has been completed by December 1, 1994. To download application materials: Send e-mail message to stisserv@nsf.gov (InterNet) or stisserv@nsf (BitNet) Ignore the subject line, but body of message should read as follows: Request: stis Topic: nsf94130 Request: end You will receive a copy of publication 94-130, the program announcement for the 1995 Summer Institute in Japan, by return e-mail. Further inquiries: Contact NSF's Japan Program staff at NSFJinfo@nsf.gov (InterNet) or NSFJinfo@nsf (BitNet) Tel: (703) 306-1701 Fax: (703) 306-0477 From owner-sci-resources@net.bio.net Fri Oct 07 23:00:00 1994 Path: biosci!biosci!not-for-mail From: pp000531@interramp.com Newsgroups: bionet.announce,bionet.sci-resources Subject: ANNOUNCE: National Technology Transfer Conference Date: 7 Oct 1994 18:39:39 -0700 Organization: PSI Public Usenet Link Lines: 279 Sender: biohelp@net.bio.net Approved: bionews-moderator@net.bio.net Distribution: world Message-ID: <3726hc$hqi@www.interramp.com> NNTP-Posting-Host: net.bio.net Xref: biosci bionet.announce:1468 bionet.sci-resources:1121 - Text following below describes the nature, purpose, program outline, and registration information for the fifth national technology transfer conference and exposition to be held this November in Washinton DC. - This is not a commercial advertisement but a news advisory of an upcoming multi-disciplinary science and technology meeting and exposition sponsored by US Government agencies and the Technology Utilization Foundation (a not-for-profit organization). Attendance at exhibits only is FREE; attendance at symposia and workshops involves registration fees. - Details contained herein are sufficient for registration by postal mail or by fax, however - a full, printed, paper registration package and program/exhibitor details can be obtained by sending an E-mail request (including your return [surface] postal mailing address) to pp000531@interramp.com who is acting on behalf of the Technology Utilization Foundation. The entity pp000531@interramp.com is Ted Morawski, MIS Director at NASA Tech Briefs, Suite 921, 41 East 42-nd Street, New York, NY. Voice tel. # 212-490-3999, Fax tel. # 212-986-7864. - More extensive descriptions of specific workshops, symposia, and exhibits are now constantly being uploaded and remain available on the Compuserve Ideas and Inventions forum (go ideas) in the Technology 2004 library which is solely devoted to this meeting and exposition. _______________________________________________________________ The Fifth National Technology Transfer Conference & Exposition November 8-10, 1994 Washington, DC Convention Center Sponsored by NASA, NASA Tech Briefs, and the Technology Utilization Foundation, in cooperation with the Federal Laboratory Consortium for Technology Transfer The federal government and its contractors will spend over $75 billion this year on research and development. Technology 2004 will show you how to tap into this tremendous resource and will introduce you to new funding and partnering opportunities. Technology 2004 will bring together the top technologists and tech transfer agents in US national laboratories, universities, and high-tech industry. It is designed to help companies to quickly and easily find innovative, ready-made ideas they can use to solve engineering problems, create new or improved products, and grow their businesses. How You Will Benefit: Practical, Informative Workshops Defense conversion...technology reinvestment, dual-use inventions. You've heard the buzzwords, but what do they mean for your company and your job? How can you take advantage of the federal government's multi-billion-dollar push to commercialize taxpayer-supported technologies and leverage the nation's R&D investment? Technology 2004 workshops will show you how to get started and what's in it for you. Symposia Spotlighting America's Best New Inventions Leading technologists from NASA, the departments of Defense and Energy, and other key agencies will unveil commercially-promising innovations and advanced processes in critical areas driving US and world growth markets. Discover how ideas developed for defense and space programs can be reapplied in commercial industries such as biotech, electronics, computing, transportation, and many more. The World's Largest Technology Transfer Exposition A "who's-who" of government labs, universities, and high-tech firms will demonstrate their latest inventions and products available for license or sale in the 80,000+ sq. ft. exhibits hall. It's the place to meet the technology vanguard, discuss your needs and capabilities you have to offer, and keep abreast of leading-edge developments across the techno-spectrum. Free Internet Training Sessions Daily demonstrations in the exhibits hall will help you to take advantage of the Internet - the worldwide web of computer networks that has been labeled "the on-ramp to the information superhighway." Learn about important resources on the net and how you can access them without spending a lot of time or money. Sessions will begin at 10:30 AM each day. Technology 2004 Program Tuesday, November 8 8:30 am - 10:00 am Plenary Session: Government-Industry Partnership Opportunities 10:30 am - 12:30 pm National Critical Technologies Concurrent Symposia: Advanced Manufacturing; Bio/Medical Technology; Computer-Aided Design; Materials Science; Power & Energy 2:00 pm - 4:00 pm Concurrent Symposia: Artificial Intelligence; Computers & Software; Electronics; Environmental Tech; Video/Imaging Exhibition Hours: 10:00 am - 5:00 pm Wednesday, November 9 8:30 am - 10:00 am Concurrent Workshops: Business Guide To Tech Transfer Resources; The Defense Technical Application Center (DTAC) Network; Small Business Innovation Research Grants 10:30 am - 12:30 pm National Critical Technologies Concurrent Symposia: Artificial Intelligence; Materials Science; Test & Measurement; Video/Imaging; Virtual Reality/Simulation 2:00 pm - 4:00 pm Concurrent Symposia: Computers & Software; Electronics; Environmental Tech; Materials Science; Test & Measurement 7:00 pm - 10:00 pm Technology Transfer Awards Dinner Exhibition Hours: 10:00 am - 5:00 pm Thursday, November 10 8:30 am - 10:00 am Concurrent Workshops: International Tech Transfer Forum; Licensing Government Patents; The Technology Reinvestment Project 10:30 am - 12:00 pm Concurrent Workshops: International Tech Transfer Forum (cont.); Cooperative Research & Development Agreements; The DOC Advanced Technology Program Exhibition Hours: 10:00 am - 3:00 pm Plus: The LaserTech '94 Photonics Technology Transfer Conference will be held concurrently with Technology 2004 on Wednesday, November 9 from 8:00 am to 4:30 pm. Complete registrants can attend the LaserTech '94 sessions, breakfast, and networking luncheon for an up-grade fee of $35.00. Preregister and $ave by 10/21 On-site Complete Registration $250 $295 (includes Technology 2004 symposia and exhibits, awards dinner, and a set of official proceedings) One-Day Registration $85 $100 Awards Dinner Only $50 $60 LaserTech '94 $35 $40 (upgrade for T2004 complete registrants; includes breakfast, lunch, and photonics symposia on 11/9) Exhibits Only - No Charge - Preregistrants will receive written confirmations via mail along with their name badges and inquiry cards. Badge holders, programs, and dinner tickets must be picked up in person at the Washington, DC Convention Center (900 Ninth St. NW) beginning at 12:00 pm on Monday, November 7. Special Hotel Rates Renaissance Hotel (headquarters) $125 single/double Grand Hyatt Washington $134 single/double Henley Park Hotel $100 single/$110 double Hotel Washington $99 single/double (govt. only) To make reservations, call the housing bureau at (800) 535-3336 or (202) 842-2930 and identify yourself as a Technology 2004 attendee. A $125 per room deposit is required. Travel Discounts Budget Rent-A-Car: Call (800) 772-3773 and refer to the Technology 2004 rate code #VNRD/TNGY. Valid Nov. 1-17. Amtrak: 10% discount. Call (800) USA-RAIL and refer to the Tech 2004 fare code #X-84E-927. Valid Nov. 6-12. USAir: Book your ticket on USAir to be entered into a drawing for two round-trip tickets good in the continental US, Canada, the Bahamas, and San Juan. 10% discount off unrestricted coach fares, and 5% off first class. Call (800) 334-8644, refer to gold file #35380094. Questions: E-mail pp000531@interramp.com Following below is a registration form that can be surface mailed or faxed, but a full printed package can also be obtained through e-mail request to pp000531@interramp.com (providing full surface-mail return address). Information requested on the registration form is not intended to disqualify anyone; it is meant to collect information regarding interest for purposes of feedback to government, industry, and the organizers. The feedback is needed for purposes of evaluation and improvement of this effort. The only restrictions are that attendance is limited to legal adults (unless prior arrangements of convenience are made), and that attendance is for legal purposes. Stuffy as it may sound in this day and age. _____________________________________________________________ TECHNOLOGY 2004 REGISTRATION FORM (DO NOT E-MAIL FOR SECURITY REASONS) Name: ___________________________________________________ Title: ____________________________________________________ Company: ________________________________________________ Address: _________________________________________________ City/St/Zip: ________________________________________________ Phone No.: __________________________________ Which of the following best describes your industry or service? (check one) A [ ] Electronics I [ ] Industrial Equipment B [ ] Computers J [ ] Manufacturing C [ ] Communications K [ ] Power/Energy D [ ] Transportation/Automotive L [ ] Biomedicine E [ ] Aerospace M [ ] University F [ ] Defense N [ ] Research Lab G [ ] Government O [ ] Other (specify below) H [ ] Materials/Chemicals ________________ Which of these products do you recommend, specify, or authorize the purchase of? (check all that apply) A [ ] Electronic Components & Systems B [ ] Software C [ ] Computers/Peripherals D [ ] CAD/CAE/CAM/CASE E [ ] Lasers/Optics F [ ] Materials G [ ] Mechanical Components H [ ] Positioning Equip./Motion Control I [ ] Test/Measurement Instruments J [ ] Sensors/Transducers K [ ] Data Acquisition L [ ] Video/Imaging Equipment M [ ] Industrial Controls/Systems N [ ] Communications Equipment O [ ] Laboratory Equipment Your principal job function is: (check one) A [ ] General & Corporate Management E [ ] Manufacturing/Production B [ ] Design & Development Engineering F [ ] Purchasing/Procurement C [ ] Engineering Services - Tests/Quality D [ ] Basic Research G [ ] Other (specify): ____________________________ Please register me for the following: A [ ] Complete Registration $250 B [ ] One-Day Symposia/Exhibits $ 85 check day: [ ] 11/8 [ ] 11/9 [ ] 11/10 C [ ] Awards Dinner Only $ 50 D [ ] LaserTech '94 upgrade fee $ 35 (D is for complete registrants only - you must have checked A above) E [ ] Exhibits Only - Free $ 0 TOTAL: $______ [ ] Check/MO enclosed (payable to Technology Utilization Foundation) [ ] Charge my: [ ] Mastercard [ ] VISA [ ] Am Ex Card No.: ____________________________ Expire Date: ______ Signature: _________________________________ Date: ____________ Registrations and Awards Dinner reservations are transferrable and may be cancelled until October 21, 1994. After that date no cancellations will be refunded. Return with payment to: Technology Utilization Foundation c/o Technology 2004, PO Box 614, Brookfield, IL 60513-0614 For fastest registration fax to: (708) 344-9482 From owner-sci-resources@net.bio.net Fri Oct 07 23:00:00 1994 Path: biosci!biosci!not-for-mail From: BIOSCI Administrator Newsgroups: bionet.sci-resources Subject: NIH GUIDE - RFA ES-94-009 - V23(35) 10/07/94 Date: 7 Oct 1994 18:46:11 -0700 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 310 Sender: biohelp@net.bio.net Approved: biosci-moderator@net.bio.net Distribution: world Message-ID: <374tl3$it7@net.bio.net> NNTP-Posting-Host: net.bio.net $$XID RFA ES94009 ES-94-009 P1O1 *************************************** MECHANISTICALLY-BASED ALTERNATIVE METHODS IN TOXICOLOGY NIH GUIDE, Volume 23, Number 35, September 30, 1994 RFA: ES-94-009 P.T. 34; K.W. 1007009 National Institute of Environmental Health Sciences Letter of Intent Receipt Date: November 15, 1994 Application Receipt Date: December 20, 1994 PURPOSE The National Institute of Environmental Health Sciences (NIEHS) invites applications to conduct research to develop mechanistically-based alternative methods and models for toxicology research and testing. Assessment of the potential adverse health effects of chemicals is currently accomplished largely by tests utilizing laboratory animals. While such traditional tests have provided information useful for human health risk assessment, improved test methods are needed that are more predictive, that provide information more supportive of quantitative risk assessment, can be achieved in a shorter time frame, and are more cost-effective. This RFA is issued to foster the development, validation, and use of improved testing and research methods that either do not require the use of animals, reduce the number of animals, or involve the use of alternatives such as non-mammalian species. This NIEHS initiative will facilitate the integration of recent advances in molecular and cellular biology and new research technologies into alternative toxicology testing methodologies that will provide improved human health hazard identification and improved dose-response relationships, thereby contributing to improved risk assessment. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority areas. This RFA, Mechanistically-Based Alternative Methods in Toxicology, is related to the priority area of Environmental Health. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017-001-00474-0) or "Healthy People 2000" (Summary Report: Stock No. 017-001-00473-1) through the Superintendent of Documents, Government Printing Office, Washington DC 20402-9325 (telephone 202-783-3238). ELIGIBILITY REQUIREMENTS Applications may be submitted by domestic and foreign for-profit and non-profit organizations, public and private, such as universities, colleges, hospitals, laboratories, units of state or local governments, and eligible agencies in the Federal government. Applications from minority individuals and women are encouraged. MECHANISM OF SUPPORT This RFA will use the National Institutes of Health (NIH) individual research project grant (R01). Responsibility for planning, direction, and execution of the proposed project will be solely that of the applicant. The total project period requested in and application may not exceed three years. FUNDS AVAILABLE The estimated funds (total costs) available for the first year of support for the entire program is $1.5 million. The expected number of awards is eight to ten. This level of support is dependent on the receipt of a sufficient number of applications of high scientific merit. Support will not be provided under this RFA for research activities focussed on clinical trials or the initiation of large-scope epidemiologic studies. RESEARCH OBJECTIVES The NIEHS proposes to expand research efforts to develop mechanistically-based alternative methods and test systems for toxicological research and testing. The development of alternative testing methods that incorporate new knowledge regarding the molecular and cellular mechanisms of toxicity will be encouraged, as well as the refinement of existing test methods/models by utilizing new scientific information and techniques such as characterization of the similarities and differences at the cellular and molecular level of test models with humans. Toxicological test methods and systems are encouraged in the priority areas of carcinogenicity, neurotoxicity, and developmental toxicity, but will be considered in any area of toxicity testing. Examples of alternative test methods and models that may be appropriate for development under each of these priority areas include: o Development of cell cultures or genetically engineered cell lines that can be used to characterize the biological activity and toxicity profiles of chemicals and classes of chemicals at the molecular and cellular level, and that are predictive of the toxic effects of chemicals in existing test species or humans. Such systems might incorporate reporter constructs that allow for the automated quantification of response. Note that cytotoxicity assays are not responsive to this RFA. o Development and utilization of transgenic animals that more closely model the human response to toxic substances and that can detect toxicant effects using fewer animals and shorter time frames. o Development and characterization of systems for toxicity testing that utilize non-mammalian or invertebrate species that are predictive of the toxic effects of chemicals in existing test species or humans. o Development and utilization of improved computer-based prediction and modeling systems for specific toxicologic endpoints. These might include physiologically-based pharmacokinetic (PBPK) models, toxicokinetic models, and biologically-based structure-activity relationship modeling/prediction system. These should include not only the design of the model, but also the design and implementation of the experiments to be conducted utilizing the model. It is anticipated that new methods/test systems worthy of further evaluation in detailed validation studies will result from the research supported by the RFA. Thus, applications submitted under this RFA must develop both a mechanistically based alternative model or test system (for example a tiered multiple system approach) and also provide sufficient evaluation to show its utility as a test/model. Thus, studies designed to simply explore the mechanism of action of a single toxicant in an alternative test/model will not be considered responsive to this RFA. SPECIAL REQUIREMENTS Applicants may request funds for one trip annually to the National Institute of Environmental Health Sciences for a meeting to discuss important new findings and a sharing of research progress. INCLUSION OF WOMEN AND MINORITIES IN RESEARCH INVOLVING HUMAN SUBJECTS It is the policy of the NIH that women and members of minority groups and their subpopulations must be included in all NIH supported biomedical and behavioral research projects involving human subjects, unless a clear and compelling rationale and justification is provided that inclusion is inappropriate with respect to the health of the subjects or the purpose of the research. This new policy results from the NIH Revitalization Act of 1993 (Section 492B of Public Law 103-43) and supersedes and strengthens the previous policies (Concerning the Inclusion of Women in Study Populations, and Concerning the Inclusion of Minorities in Study Populations), which have been in effect since 1990. The new policy contains some provisions that are substantially different from the 1990 policies. All investigators proposing research involving human subjects should read the "NIH Guidelines For Inclusion of Women and Minorities as Subjects in Clinical Research," which have been published in the Federal Register of March 28, 1994 (FR 59 14508-14513), and reprinted in the NIH Guide for Grants and Contracts, Volume 23, Number 11, March 18, 1994. Investigators may obtain copies of the policy from the program staff listed under INQUIRIES. Program staff may also provide additional relevant information concerning the policy. LETTER OF INTENT Prospective applicants are asked to submit, by November 15, 1994, a letter of intent that includes the title of the proposed project, a short descriptive abstract, the name, address, and telephone number of the Principal Investigator, and RFA title and number. Although a letter of intent is not required, is not binding, and does not enter into the review of the subsequent application, the information that it contains is helpful in planning for the review of applications. It allows the NIEHS staff to estimate the potential review workload and to avoid conflict of interest in the review. The letter of intent is to be sent: Dr. Ethel Jackson Division of Extramural Research and Training National Institute of Environmental Health Sciences P.O. Box 12233 Building 17, Room 1717 104 TW Alexander Drive Research Triangle Park, NC 27709 Telephone: (919) 541-7826 FAX: (919) 541-2503 APPLICATION PROCEDURES The research grant application form PHS 398 (rev. 9/91) is to be used in applying for these grants. These forms are available at most institutional offices of sponsored research and from the Office of Grants Information, Division of Research Grants, National Institutes of Health, 5333 Westbard Avenue, Room 449, Bethesda, MD 20892, telephone (301) 594-7378. Applications must be received by December 20, 1994. If an application is received after that date, it will be returned to the applicant. Submit a signed, typewritten original of the application, including the Checklist, and three signed, photocopies, in one package to: Division of Research Grants National Institutes of Health Westwood Building, Room 240 Bethesda, MD 20892** At the time of submission, two additional copies of the application must also be sent to Dr. Ethel Jackson at the address listed under LETTER OF INTENT. REVIEW CONSIDERATIONS Upon receipt, applications will be reviewed by NIH staff for completeness and responsiveness. Incomplete applications will be returned to the applicant without further consideration. If the application is not responsive to the RFA, NIEHS staff will contact the applicant to determine whether to return the application to the applicant or submit it for review in competition with unsolicited applications at the next review cycle. Applications that are complete and responsive to the RFA will be evaluated for scientific and technical merit by an appropriate peer review group convened by the NIEHS in accordance with the review criteria stated below. As part of the initial merit review, a process (triage) may be used by the initial review group in which applications will be determined to be competitive or non-competitive based on their scientific merit relative to other applications received in response to the RFA. Applications judged to be competitive will be discussed and be assigned a priority score. Applications determined to be non-competitive will be withdrawn from further consideration and the Principal Investigator and the official signing for the applicant organization will be notified. The second level of review will be provided by the National Advisory Environmental Health Sciences Council. Review criteria for RFAs are generally the same as those for unsolicited research grant applications. o scientific, technical, or medical significance and originality of proposed research; o appropriateness and adequacy of the experimental approach and methodology proposed to carry out the research; o qualifications and research experience of the Principal Investigator and staff, particularly but not exclusively in the area of the proposed research; o availability of resources necessary to perform the research; o appropriateness of the proposed budget and duration in relation to the proposed research. The subject of this RFA may overlap interests of other Institutes, Centers and Divisions (ICDs). Applications will, therefore, be assigned according to extant Referral Guidelines. AWARD CRITERIA This anticipated date of award is July 1, 1994. The following will be considered in making funding decisions. o quality of proposed programs as determined by peer review, o availability of funds; and o program balance among research areas of the RFA. INQUIRIES Inquiries concerning this RFA are encouraged. The opportunity to clarify any issues or questions from potential applicants is welcome. Direct inquiries regarding programmatic issues to: Jerrold J. Heindel, Ph.D. Division of Extramural Research and Training National Institute of Environmental Health Sciences P.O. Box 12233, 104 T.W. Alexander Drive Research Triangle Park, NC 27709 Telephone: (919) 541-0781 FAX: (919) 541-2843 Email: Heindel_J@NIEHS.NIH.GOV Direct inquiries regarding fiscal matters to: Mr. David L. Mineo Division of Extramural Research and Training National Institute of Environmental Health Sciences P.O. Box 12233 104 T.W. Alexander Drive Research Triangle Park, NC 27709 Telephone: (919) 541-1371 AUTHORITY AND REGULATIONS This program is described in the Catalog of Federal Domestic Assistance No. 93.113 and 93.115. Awards are made under authorization of the Public Health Service Act, Title IV, Part A (Public Law 78-410, as amended by Public Law 99-158, 43 USC 241 and 285) and administered under PHS grants policies and Federal Regulations 42 CFR 52 and 45 CFR Part 74. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review. The Public Health Service (PHS) strongly encourages all grant recipients to provide a smoke-free workplace and promote the non-use of all tobacco products. This is consistent with the PHS mission to protect and advance the physical and mental health of the American people. From owner-sci-resources@net.bio.net Sun Oct 09 23:00:00 1994 Path: biosci!biosci!not-for-mail From: BIOSCI Administrator Newsgroups: bionet.sci-resources Subject: NSF - Summary of new documents on STIS - 9 October 1994 Date: 10 Oct 1994 02:46:57 -0700 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 110 Sender: kristoff@net.bio.net Approved: biosci-moderator@net.bio.net Distribution: world Message-ID: <37b2ih$ccc@net.bio.net> NNTP-Posting-Host: net.bio.net This message contains a summary of the documents added to the NSF STIS system in the previous week. Reference material concerning STIS follows the summary. ------------------------------------------------------------------------ ** NEW DOCUMENTS ON STIS ** Document Type: General Publication Title: NSF 94-2a Grant Proposal Guide - Appendix A File size (bytes): 14477 STIS Filename: nsf942a Also available: nsf942a.doc Title: NSF 94-2c Grant Proposal Guide - Appendix C File size (bytes): 2628 STIS Filename: nsf942c Also available: nsf942c.doc Document Type: News Title: Media Tipsheet October 7, 1994 File size (bytes): 3911 STIS Filename: tip41007 Document Type: Press Release Title: "SUPERSONIC ABRASIVE ICE-BLASTING," AN ENVIRONMENTALLY FRIENDLY METHOF OF REMOVING PAINT OR GREASE FROM SURFACES, DEVELOPED WITH NSF FUNDING File size (bytes): 6057 STIS Filename: pr9458 Document Type: Program Guideline Title: NSF 94-122 - Human Resource Development for Minorities in Science and Engineering File size (bytes): 164331 STIS Filename: nsf94122 Also available: nsf94122.ps Title: NSF 94-146 -- Doctoral Dissertation Improvement Grants In The Directorate For Biological Sciences File size (bytes): 11639 STIS Filename: nsf94146 Document Type: SRS Report Title: NSF 94-305--Science and Engineering Degrees- 1966-91 File size (bytes): 5328 STIS Filename: nsf94305 Also available: nsf94305.zip ------------------------------------------------------------------------ ** UPDATES TO EXISTING STIS DOCUMENTS ** Document Type: Program Guideline Title: NSF 94-147 -- RESEARCH PLANNING GRANTS AND CAREER ADVANCEMENT AWARDS FOR MINORITY SCIENTISTS AND ENGINEERS File size (bytes): 43070 STIS Filename: nsf94147 Document Type: SRS Report Title: NSF 93-309 -- Academic Science and Engineering- Graduate Enrollment and Support Fall -1991 File size (bytes): 37512 STIS Filename: nsf93309 Also available: nsf93309.zip ------------------------------------------------------------------------ ** FOR YOUR REFERENCE ** ------------------------------------------------------------------------ HOW TO OBTAIN DOCUMENTS The above files can be retrieved in electronic form using the STIS system. If you don't know how to use STIS, send an E-mail message to stisinfo@nsf.gov (Internet). You will receive a copy of the STIS flyer via E-mail. If you are already using STIS, you can use the information above to retrieve these files: Documents via E-mail: Send a message to stisserve@nsf.gov (Internet). Use the "STIS Filename" shown above in the "get" command. For example, to retrieve nsf93309, the text of your message should be as follows: get nsf93309 Anonymous FTP: FTP to stis.nsf.gov. Use the "STIS Filename" shown above to retrieve a file. For example, to retrieve nsf93309, you would enter: ftp> get nsf93309 WAIS or Gopher: Do a word search on the filename as shown in the summary. If you want a *printed* copy of a document: Send your name and postal mailing address, and the document title and number to "pubs@nsf.gov" (Internet). If you have problems with the above procedures: Send a message to "stis@nsf.gov" (Internet). From owner-sci-resources@net.bio.net Sun Oct 09 23:00:00 1994 Path: biosci!biosci!not-for-mail From: BIOSCI Administrator Newsgroups: bionet.sci-resources Subject: NIH Guide, vol. 23, no. 35, pt. 1of1, 7 October 1994 Date: 10 Oct 1994 03:26:41 -0700 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 1147 Sender: biohelp@net.bio.net Approved: biosci-moderator@net.bio.net Distribution: world Message-ID: <37b4t1$e8r@net.bio.net> NNTP-Posting-Host: net.bio.net $$XID NIHGUIDE 19941007 V23N35 P1O1 ************************************ X-comment: RFAS described: ES-95-002, CA-95-002, DK-95-001, HL-95-003, HL-95- 004, HL-95-005, HL-95-006, ES-94-009, PA-95-001 NIH GUIDE - Vol. 23, No. 35 - October 7, 1994 $$INDEX BEGIN ******************************************************* NOTICES $$INDEX N1 ********************************************************** NATIONAL HUMAN SUBJECT PROTECTIONS WORKSHOPS National Institutes of Health Food and Drug Administration INDEX: NATIONAL INSTITUTES OF HEALTH; FOOD AND DRUG ADMINISTRATION $$INDEX N2 ********************************************************** SUMMARY OF TECHNICAL REVIEWS AVAILABLE ON NIDA BBS National Institute on Drug Abuse INDEX: DRUG ABUSE $$INDEX N3 ********************************************************** NIGMS MOVES TO NATCHER BUILDING, REORGANIZES National Institute of General Medical Sciences INDEX: GENERAL MEDICAL SCIENCES NOTICES OF AVAILABILITY (RFPs/RFAs/PAs) $$INDEX R1 ********************************************************** CLINICAL COORDINATING CENTER FOR ETIOLOGY OF SARCOIDOSIS: A CASE CONTROL STUDY (RFP NHLBI-HR-94-20) National Heart, Lung, and Blood Institute INDEX: HEART, LUNG, BLOOD $$INDEX R2 ********************************************************** TECHNICAL, ANALYTICAL AND SUPPORT SERVICES FOR THE NHLBI (RFP NHLBI-HO-94-33) National Heart, Lung, and Blood Institute INDEX: HEART, LUNG, BLOOD $$INDEX R3 ********************************************************** 1996-1997 NATIONAL SURVEY OF THE ORAL HEALTH OF U.S. SCHOOLCHILDREN (RFP NIH-NIDR-4-94-10R) National Institute of Dental Research INDEX: DENTAL RESEARCH $$INDEX R4 01/13/95 ************************************************* ENVIRONMENTAL JUSTICE: PARTNERSHIPS FOR COMMUNICATION (RFA ES-95-002) National Institute of Environmental Health Sciences INDEX: ENVIRONMENTAL HEALTH SCIENCES $$INDEX R5 02/17/95 ************************************************* OCCUPATIONAL EXPOSURE AND CANCER PREVENTION/CONTROL RESEARCH (RFA CA-95-002) National Cancer Institute National Institute of Occupational Safety and Health INDEX: CANCER; OCCUPATIONAL SAFETY, HEALTH $$INDEX R6 03/16/95 ************************************************* DIABETES RESEARCH AND TRAINING CENTER (RFA DK-95-001) National Institute of Diabetes and Digestive and Kidney Diseases INDEX: DIABETES, DIGESTIVE, KIDNEY $$INDEX R7 03/29/95 ************************************************* BEHAVIORAL INTERVENTIONS FOR CONTROL OF TUBERCULOSIS (RFA HL-95-003) National Heart, Lung, and Blood Institute INDEX: HEART, LUNG, BLOOD $$INDEX R8 04/11/95 ************************************************* THE ETIOLOGY OF EXCESS CARDIOVASCULAR DISEASE IN DIABETES MELLITUS (RFA HL-95-004) National Heart, Lung and Blood Institute INDEX: HEART, LUNG, BLOOD $$INDEX R9 05/18/95 ************************************************* ISCHEMIC HEART DISEASE IN BLACKS (RFA HL-95-005) National Heart, Lung and Blood Institute INDEX: HEART, LUNG, BLOOD $$INDEX R10 12/08/95 ************************************************ SPECIALIZED CENTERS OF RESEARCH IN MOLECULAR MEDICINE AND ATHEROSCLEROSIS (RFA HL-95-006) National Heart, Lung, and Blood Institute INDEX: HEART, LUNG, BLOOD $$INDEX R11 12/20/94 ************************************************ MECHANISTICALLY-BASED ALTERNATIVE METHODS IN TOXICOLOGY (RFA ES-94-009) National Institute of Environmental Health Sciences INDEX; ENVIRONMENTAL HEALTH SCIENCES $$INDEX P1 ********************************************************** FACTORS THAT DETERMINE THERAPEUTIC DRUG BIOAVAILABILITY (PA-95-001) National Institute of General Medical Sciences INDEX: GENERAL MEDICAL SCIENCES This publication is available electronically to institutions via BITNET or INTERNET and is also on the NIH GOPHER. Alternative access is through the NIH Grant Line using a personal computer (data line 301/402-2221). Contact Dr. John James at 301/594-7270 for details. THE PUBLIC HEALTH SERVICE (PHS) STRONGLY ENCOURAGES ALL GRANT RECIPIENTS TO PROVIDE A SMOKE-FREE WORKPLACE AND PROMOTE THE NON-USE OF ALL TOBACCO PRODUCTS. THIS IS CONSISTENT WITH THE PHS MISSION TO PROTECT AND ADVANCE THE PHYSICAL AND MENTAL HEALTH OF THE AMERICAN PEOPLE. $$INDEX END ********************************************************* NOTICES $$N1 BEGIN ********************************************************** NATIONAL HUMAN SUBJECT PROTECTIONS WORKSHOPS NIH GUIDE, Volume 23, Number 35, October 7, 1994 P.T. 42; K.W. 0783005 National Institutes of Health Food and Drug Administration The National Institutes of Health (NIH) and the Food and Drug Administration (FDA) are continuing to sponsor a series of workshops on responsibilities of researchers, Institutional Review Boards (IRBs), and institutional officials for the protection of human subjects in research. The workshops are open to everyone with an interest in research involving human subjects. The meetings should be of special interest to those persons currently serving or about to begin serving as a member of an IRB. Issues discussed at these workshops are relevant to all other Public Health Service agencies. The current schedule includes: DATES: December 8-9, 1994 LOCATION Seven Hills Center San Francisco State University San Francisco, CA SPONSORS San Francisco State University, San Francisco, CA California State University, Los Angeles, CA REGISTRATION Darlene Yee, Ph.D. Chair, Committee for the Protection of Human Subjects Office of Research Sponsored Programs San Francisco State University 20 Tapia Drive San Francisco, CA 94132 Telephone: (415) 452-1908 FAX: (415) 338-6378 TITLE: Current Issues in Research Involving Human Subjects DESCRIPTION: Institutional Review Boards (IRBs) are charged with responsibilities for ethical review and oversight of the use of human subjects in research protocols. The primary principle governing the IRB's review and action is the protection of human subjects from risks while permitting the advancement of research. IRBs are faced today with complex concerns that require deep ethical and moral judgements, and they are challenged to act in an objective and timely fashion. Our workshop will focus on current issues in research involving human subjects: evolving concerns for protection of human subjects from research risks; FDA regulatory update; new guidelines on the inclusion of women and communities of color in clinical research; guidelines for human embryo research; ethics and philosophy of research with vulnerable populations such as children, the elderly, and those who are cognitively impaired and/or physically challenged; lessons learned from historical episodes in research; changing demographics of research in California; and emerging issues in research involving prisoners. The workshop formats will include facilitated forums, information exchanges, panel discussions, and active audience participation. We have assembled an outstanding faculty of distinguished experts to provide authoritative and provocative discussion of challenging issues in the field of human subjects research review. Participants will (1) learn how Federal regulations and community participation can protect human subjects in research, (2) become familiar with the issues involved in protecting the rights of vulnerable populations in research, (3) explore how regulations and community participation can collaborate to protect human subjects, (4) become more knowledgeable about policies, procedures, and expectations of an IRB, and (5) discuss the rights and responsibilities of researchers. INQUIRIES For further information regarding these workshops or future NIH/FDA National Human Subject Protections Workshops, contact: Ms. Darlene Marie Ross Office for Protection from Research Risks National Institutes of Health Building 31, Room 5B-59 Rockville, MD 20892-2018 Telephone: (301) 496-8101 FAX: (301) 402-0527 $$N1 END ************************************************************ $$N2 BEGIN ********************************************************** SUMMARY OF TECHNICAL REVIEWS AVAILABLE ON NIDA BBS NIH GUIDE, Volume 23, Number 35, October 7, 1994 P.T. 16; K.W 0404009 National Institute on Drug Abuse Summaries of National Institute on Drug Abuse (NIDA) technical reviews are now available on NIDA's Bulletin Board System. Current summaries available include: 1. Cocaine Induced Neurotoxicity: Implications for Treatment 2. Qualitative Methods in Drug Abuse and HIV Research 3. Prevention Interventions with African American Populations 4. Laboratory Behavioral Studies of Vulnerability to Drug Abuse The NIDA bulletin board is a selection on the NIH Bulletin Board System and can be reached at 1-800-358-2221. Modem settings are 7 data bits, even parity and 1 stop bit. Logon initials FN5 and account FNF1 have been established for use by the public at no charge. INQUIRIES For additional information, contact Connie Latzko Information Resource Management Branch National Institute on Drug Abuse 5600 Fishers Lane Parklawn Building, Room 11A41 Rockville, MD 20857 Telephone: (301) 443-6910 Email: cl77g@nih.gov $$N2 END ************************************************************ $$N3 BEGIN ********************************************************** NIGMS MOVES TO NATCHER BUILDING, REORGANIZES NIH GUIDE, Volume 23, Number 35, October 7, 1994 P.T.34; K.W. 1014006 National Institute of General Medical Sciences On October 7, 1994, the staff of the National Institute of General Medical Sciences (NIGMS) moves to the new William H. Natcher Building on the main NIH campus. The mailing address is: (Name of staff member) NIGMS, NIH 45 Center Drive MSC 6200 Bethesda, MD 20892-6200 Telephone and FAX numbers are changing as well. Listed below are the new telephone numbers for key NIGMS staff members. For the telephone number of an NIGMS staff member who is not included on this list, call the person's old number (a recording will give the new number for several weeks) or call the NIGMS Office of Research Reports at (301) 496-7301. The following list also reflects the NIGMS' reorganization, effective October 1, 1994. The reorganization was undertaken to enhance the NIGMS' effectiveness and efficiency in supporting basic biomedical research and research training, as well as to align NIGMS' organizational structure and position titles with those of other NIH institutes. The most significant change is the rearrangement of four program branches--Cellular and Molecular Basis of Disease, Genetics, Biophysics and Physiological Sciences, and Pharmacology and Biorelated Chemistry--into three divisions: Cell Biology and Biophysics; Genetics and Developmental Biology; and Pharmacology, Physiology, and Biological Chemistry. In addition, the recently established Minority Opportunities in Research Programs Branch becomes the Division of Minority Opportunities in Research. The reorganization is not intended to reflect changes in NIGMS support for specific areas of science; in fact, the grant portfolios managed by individual program administrators will remain essentially the same. For additional information on the reorganization, contact the NIGMS Office of Research Reports at the above telephone number. Acting Director, Marvin Cassman, Ph.D. -- (301) 594-2172 Executive Officer, Martha Pine -- (301) 594-2755 Personnel Officer, Howard Chernoff -- (301) 594-2749 Equal Employment Opportunity Officer, Karen Basnight -- (301) 594-2751 Associate Director for Extramural Activities, W. Sue Shafer, Ph.D. -- (301) 594-4499 Chief, Grants Administration Branch, Carol Tippery -- (301) 594-5135 Assistant Director for Referral and Liaison, Anthony Rene, Ph.D. -- (301) 594-3833 Assistant Director for Research Training, John Norvell, Ph.D. -- (301) 594-0533 Director, Division of Cell Biology and Biophysics, James Cassatt, Ph.D. -- (301) 594-0828 Director, Division of Genetics and Developmental Biology, Judith Greenberg, Ph.D. -- (301) 594-0943 Director, Division of Minority Opportunities in Research, Clifton Poodry, Ph.D. -- (301) 594-3900 Acting Director, Division of Pharmacology, Physiology, and Biological Chemistry, Michael Rogers, Ph.D. -- (301) 594-3827 Chief, Office of Scientific Review, Helen Sunshine, Ph.D. -- (301) 594- 3663 $$N3 END ************************************************************ NOTICES OF AVAILABILITY (RFPs AND RFAs) $$R1 BEGIN NHLBI-HR-94-20 ******************************************* CLINICAL COORDINATING CENTER FOR ETIOLOGY OF SARCOIDOSIS: A CASE CONTROL STUDY NIH GUIDE, Volume 23, Number 35, October 7, 1994 RFP AVAILABLE: NHLBI-HR-94-20 P.T. 34; K.W. 0755030, 0765034, 0755018 National Heart, Lung, and Blood Institute The overall objective of this program is to support a six year multi-center case-control study on the potential etiologic factors for sarcoidosis. This program will consist of up to twelve clinical centers which will recruit 840 sarcoidosis patients and 1680 control subjects for study over a four year period. The cases will also be followed to gain information on the natural history of this disease including risk factors for progression of disease. The protocol to be developed during Phase I (12 Months) will include a comprehensive clinical characterization of each participant and determination of markers of immune responsiveness. During Phase II (48 Months) the coordinating center will collect, manage and analyze the data from the clinical centers. In addition, the coordinating center will organize and manage the biological banking system in collaboration with the NHLBI-supported repository. The clinical coordinating center will: (1) assume leadership in areas of statistics and epidemiology for the study; (2) coordinate and manage meetings of the steering committee with direction from NHLBI; (3) participate in steering committee meetings and produce and distribute minutes of these meetings; (4) interact with the clinical centers in preparing the specific study protocol, reporting forms, and the manual of operations; (5) assist the Project Officer in preparing the agendas for periodic meetings of the Policy Board and make presentations at the Policy Board meetings; (6) standardize, print, and distribute reporting forms, the study protocol, and the manual of operations; (7) receive, collect, process, store, provide quality control and analyze data collected from the participating clinical centers; (8) prepare and distribute periodic technical and statistical reports to the participating clinical centers, the project officer, and the contracting officer. During Phase III (12 Months) the coordinating center will collaborate with the other study investigators and project officer in developing and writing manuscripts describing results of the study. Coordinating Center staff will collaborate fully in the development of the study protocol, monitor the clinical centers to ensure that data are reviewed for completeness and that quality control is maintained prior to processing, and conduct proper statistical analysis of the data. Under the direction of the Principal Investigator, these persons will monitor the clinical centers' activities to insure that: (1) data are forwarded in accordance with an established time schedule, (2) data are reviewed for accuracy and completeness, (3) quality control is maintained prior to and during processing of data, and (4) data is analyzed using appropriate statistical tests. This proposed program is a 100 percent set-aside for small business competition. Only responsible small business firms as defined in Part 19 of the Federal Acquisition Regulation are asked to respond to this synopsis. The Standard Industrial Classification (SIC) Code is 7379. This announcement is for a clinical coordinating center only. A separate Request for Proposals (RFP) for the clinical centers will be released. INQUIRIES RFP NHLBI-HR-94-20 is now available and proposals are due on or about November 1, 1994. Copies of the RFP may be obtained by submitting a written request along with three self-addressed mailing labels to: Pamela S. Randall Contracts Operations Branch National Heart, Lung, and Blood Institute Westwood Building, Room 654 Bethesda, MD 20892 $$R1 END ************************************************************ $$R2 BEGIN NHLBI-HO-94-33 ******************************************* TECHNICAL, ANALYTICAL AND SUPPORT SERVICES FOR THE NATIONAL HEART, LUNG, AND BLOOD INSTITUTE NIH GUIDE, Volume 23, Number 35, October 7, 1994 RFP AVAILABLE: NHLBI-HO-94-33 P.T. 01; K.W. 0780000 National Heart, Lung, and Blood Institute The National Heart, Lung, and Blood Institute (NHLBI) will make available to interested offerors a request for proposal (RFP) to provide services in support of the National Heart, Blood Vessel, Lung, and Blood Diseases and Blood Resources Program. The NHLBI supports and/or sponsors a variety of task forces, conferences, and workshops and prepares numerous reports and technical documents. Many of these activities are related to assessment of the state of knowledge in a particular disease or problem area, identification of progress in that area, and formulating recommendations for future research. Support services are required to assist in conducting such activities and in preparing resulting reports and proceedings. There are three basic services to be provided. The first service is to provide administrative support to scientific working groups. This work will include the making of logistical arrangements for scientific meetings of technical experts; development, preparation, and distribution of technical and other support materials for meetings; documentation of meetings; and preparation of summary materials. The second major service is to provide documentation support to the NHLBI. This work will involve the preparation and reproduction of scientific documents and documentation support for preparation of reports and briefing materials including required editing. The third major service involves providing analytical support to the NHLBI. This task includes the compilation and interpretation of scientific and administrative data and the development of suitable graphs, tables and narratives. This task also involves the analysis and documentation of existing programs and support systems and will be followed by development and implementation of new or updated systems. The contract period of performance will be for five years. The project staff of the successful offeror must be available to meet with NHLBI program staff at the NIH in Bethesda, Maryland with as little as two hours advance notice. INQUIRIES This announcement is not an RFP. It is anticipated that RFP NHLBI-HO-94-33 is not available. Copies of the RFP may obtained by submitting a written request and three self-addressed mailing labels to: Douglas W. Frye Contracts Operations Branch, DEA National Heart, Lung, and Blood Institute Federal Building, Room 4C04 7550 Wisconsin Avenue, MSC 9070 Bethesda, MD 20892-9070 Telephone: (301) 496-6838 FAX: (301) 496-9501 To ensure timely receipt of requests for RFP No. NHLBI-HO-94-33, facsimile requests will be accepted. $$R2 END ************************************************************ $$R3 BEGIN NIH-NIDR-4-94-10R **************************************** 1996-1997 NATIONAL SURVEY OF THE ORAL HEALTH OF U.S. SCHOOLCHILDREN (OHSC III) NIH GUIDE, Volume 23, Number 35, October 7, 1994 RFP AVAILABLE: NIH-NIDR-4-94-10R P.T. 34; K.W. 0404021, 0715148, 0785055 National Institute of Dental Research The National Institute of Dental Research (NIDR) has a requirement for the design and implementation of a nationwide oral epidemiologic survey of U.S. schoolchildren, grades K through 12. The survey will provide the database for a historical analysis of trends in dental caries and other oral health characteristics of U.S. schoolchildren. It will provide, for the first time, statistically reliable estimates of the oral health of Black and Hispanic schoolchildren in the United States. The objectives of this survey are to: (1) assess the relative frequency and sociodemographic distribution of certain oral diseases and disorders in U.S. schoolchildren, (2) over-sample selected minority schoolchildren to provide statistically reliable baseline national estimates of oral health for Black non-Hispanic and Hispanic schoolchildren, and (3) provide the database for the late nineties, needed to evaluate shorter- and longer-term trends in coronal caries and certain other oral diseases and disorders. INQUIRIES This is an announcement of an anticipated Request for Proposal (RFP). RFP No. NIH-NIDR-4-94-10R will be available approximately October 21, 1994, with a closing date tentatively set for December 16, 1994. Requests for the RFP must be submitted in writing, addressed to: Marion L. Blevins Contract Management Section National Institute of Dental Research Westwood Building, Room 533 Bethesda, MD 20892 $$R3 END ************************************************************ $$R4 BEGIN ES-95-002 FULL-TEXT ************************************** ENVIRONMENTAL JUSTICE: PARTNERSHIPS FOR COMMUNICATION NIH GUIDE, Volume 23, Number 35, October 7, 1994 RFA AVAILABLE: ES-95-002 P.T. 34; K.W. 0725030, 0730050 National Institute of Environmental Health Sciences Letter of Intent Receipt Date: November 17, 1994 Application Receipt Date: January 13, 1995 PURPOSE The purpose of this program is to strengthen the NIEHS effort that supports research aimed at achieving environmental justice for socioeconomically disadvantaged and medically underserved populations in the United States. The main objective of this RFA is to establish methods for linking members of a community, who are directly affected by adverse environmental conditions, with researchers and health care providers. The estimated total funds available for the first year of support are anticipated to be $500,000. It is anticipated that one to three grants will be awarded depending upon the availability of funds for this purpose and the quality of the applications received. Awards are not renewable and supplements are not allowed. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority areas. This RFA, Environmental Justice: Partnerships for Communication, is related to the priority area of environmental health. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017-001-00474-0) or "Healthy People 2000" (Summary Report: Stock No. 017-001-00473-1) through the Superintendent of Documents, Government Printing Office, Washington DC 20402-9325 (telephone 202-783-3238). INQUIRIES The RFA, which describes the research objectives, application procedures, review considerations and award criteria for this solicitation, may be obtained electronically through the NIH Grant Line (data line 301-402-2221) and the NIH GOPHER via Internet, and in print from the program contact listed below. Allen Dearry, Ph.D. Division of Extramural Research and Training National Institute of Environmental Health Sciences P.O. Box 12233, MD 3-02 Research Triangle Park, NC 27709 Telephone: (919) 541-7825 / 4943 FAX: (919) 541-2843 EMAIL: DEARRY@NIEHS.NIH.GOV $$R4 END ************************************************************ $$R5 BEGIN CA-95-002 FULL-TEXT ************************************** OCCUPATIONAL EXPOSURE AND CANCER PREVENTION/CONTROL RESEARCH NIH GUIDE, Volume 23, Number 35, October 7, 1994 RFA AVAILABLE: CA-95-002 P.T. 34; K.W. 0725020, 0715035, 0745027 National Cancer Institute National Institute of Occupational Safety and Health Letter of Intent Receipt Date: January 10, 1995 Application Receipt Date: February 17, 1995 PURPOSE The purpose of this Request for Applications (RFA) is to stimulate innovative epidemiologic studies aimed at promoting cancer control research activities. Approximately $2.0 million per year in total costs for four years will be committed by the National Cancer Institute (NCI) to specifically fund applications submitted in response to this RFA. In addition, $300,000 per year in total costs will be committed by the National Institute of Occupational Safety and Health (NIOSH) to fund at least one application. The expected number of awards is six to eight. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority areas. This RFA, Occupational Exposure and Cancer Prevention/Control Research, is related to the priority area of cancer. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017-001-00474-0) or "Healthy People 2000" (Summary Report: Stock No. 017-001-00473-1) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325 (telephone 202/783-3238). INQUIRIES The RFA, which describes the research objectives, application procedures, review considerations and award criteria for this solicitation, may be obtained electronically through the NIH Grant Line (data line 301-402-2221) and the NIH GOPHER (gopher.nih.gov) and by mail and email from the program contacts listed below. Richard L. Bragg, Ph.D. Division of Cancer Prevention and Control National Cancer Institute 6130 Executive Boulevard MSC 7395 Executive Plaza North, Suite 240 Bethesda, MD 20892-7395 Telephone: (301) 496-8589 FAX: (301) 496-8675 Roy M. Fleming, Sc.D. National Institute of Occupational Safety and Health 1600 Clinton Road, NE Building l, Room 3053, Mail Stop D-30 Atlanta, GA 30333 Telephone: (404) 639-3343 FAX: (404) 639-2196 $$R5 END ************************************************************ $$R6 BEGIN DK-95-001 FULL-TEXT ************************************** DIABETES RESEARCH AND TRAINING CENTER NIH GUIDE, Volume 23, Number 35, October 7, 1994 RFA AVAILABLE: DK-95-001 P.T. 04; K.W. 0715075, 0720005, 0710030 National Institute of Diabetes and Digestive and Kidney Diseases Letter of Intent Receipt Date: February 16, 1995 Application Receipt Date: March 16, 1995 PURPOSE The National Institute of Diabetes, Digestive and Kidney Diseases (NIDDK) supports six Diabetes Research and Training Centers (DRTCs). These Centers are part of an integrated program of diabetes-related research support within the NIDDK. Centers have provided a focus for increasing the efficiency and collaborative effort among groups of successful investigators at institutions with established comprehensive diabetes research bases. The NIDDK invites applications for funding of one DRTC grant to be competitively awarded in Fiscal Year 1996. Support of this program will be through the National Institutes of Health (NIH) comprehensive center (P60) award. The NIDDK anticipates awarding one DRTC Grant in Fiscal Year 1996 on a competitive basis. The receipt of one competing continuation application is anticipated, which will be in competition together with the other applications received in response to this announcement. The anticipated award will be for five years and will be contingent upon the availability of appropriated funds. Requests for support must be limited to no more than $1,250,000 in direct costs per year. Requests for support for Demonstration and Education (D&E) supplements to convert an existing DERC to a DRTC must be limited to $300,000 in direct costs. If awarded, the D&E supplement funding would be added to the level of the existing DERC budget. The $1,250,000 direct cost application limit would then apply to future DRTC competing renewals. The NIDDK has allocated $1,657,000 in total costs to support this RFA. Any application exceeding the direct cost amounts indicated will be returned to the applicant. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority areas. This RFA, Diabetes Research and Training Centers, is related to the priority area of diabetes mellitus. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017-001-00474-0) or "Healthy People 2000" (Summary Report: Stock No. 017-001-00473-1) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325 (telephone: (202) 783-3238). INQUIRIES The RFA, which describes the research objectives, application procedures, review considerations and award criteria for this solicitation, may be obtained electronically through the NIH Grant Line (data line 301-402-2221) and the NIH GOPHER via Internet, and in print from the program contact listed below. Dr. Sanford A. Garfield Division of Diabetes, Endocrinology, and Metabolic Diseases National Institute of Diabetes and Digestive and Kidney Diseases Westwood Building, Room 626 45 Center DR MSC 6600 Bethesda, MD 20892 Telephone: (301) 594-7535 FAX: (301) 594-9011 $$R6 END ************************************************************ $$R7 BEGIN HL-95-003 FULL-TEXT ************************************** BEHAVIORAL INTERVENTIONS FOR CONTROL OF TUBERCULOSIS NIH GUIDE, Volume 23, Number 35, October 7, 1994 RFA AVAILABLE: HL-95-003 P.T. 34; K.W. 0715165, 0745027, 0404000 National Heart, Lung, and Blood Institute Letter of Intent Receipt Date: February 15, 1995 Application Receipt Date: March 29, 1995 PURPOSE The purpose of this solicitation is to encourage research to develop, implement, and evaluate behavioral interventions for the control of tuberculosis. Plans that include the development, implementation, and evaluation of programs that can serve as models for other areas of the country will be given priority for consideration. This RFA solicits applications for the National Institutes of Health (NIH) individual research project grant (R01) support mechanism. The estimated funds (total costs) available for the first year of support for the entire program is $1.84 million. It is anticipated that no more than five awards will be issued under this program. Since a variety of approaches would represent valid responses to this RFA, it is anticipated that there will be a range of costs among individual grants awarded. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority